Volume 2; Issue 8

European Journal of Cancer Supplements

Volume 2; Issue 8

1

Editorial board

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 26 KB

english, 2004

2

Welcome address

Jaap Verweij, Alexander M.M. Eggermont

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 51 KB

english, 2004

3

Societies' profiles

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 208 KB

english, 2004

4

Conference committees

Journal:

European Journal of Cancer Supplements

Year:

2004

File:

PDF, 29 KB

2004

5

Acknowledgements

Journal:

European Journal of Cancer Supplements

Year:

2004

File:

PDF, 26 KB

2004

6

Alphabetical list of exhibitors on 17 August 2004

Journal:

European Journal of Cancer Supplements

Year:

2004

File:

PDF, 26 KB

2004

7

Exhibition floor plan

Journal:

European Journal of Cancer Supplements

Year:

2004

File:

PDF, 45 KB

2004

8

General information

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 165 KB

english, 2004

9

Scientific programme - overview

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

10

Scientific programme - details

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 1.34 MB

english, 2004

11

1 How to develop a successful cancer drug — molecules to medicines or targets to treatments?

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 125 KB

english, 2004

12

2 Pitfalls in developing cancer chemoprevention agents

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 125 KB

english, 2004

13

3 Overview of proteomics with emphasis on diagnosis and monitoring

E.C. Kohn, E.M. Posadas, V. Espina, V. Kwitkowski, B. Davidson, E.F. Petricoin, L. Liotta

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 125 KB

english, 2004

14

4 High throughput genome sequencing for cancer gene discovery: BRAF and beyond

R. Wooster, P.J. Stephens, H.R. Davies, C. Hunter, G.R. Bignell, R. Smith, M.R. Stratton, P.E. Futrea

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 125 KB

english, 2004

15

5 Towards a high throughput platform for quantitative serum protein profiling

R. Aebersold, X. Li, E. Yi, P. Mallick, H. Zhang

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 125 KB

english, 2004

16

6 Genomics and proteomics in drug development

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 90 KB

english, 2004

17

7 Mapping and targeting proteins at the endothelial cell surface and its caveolae for improved penetration, imaging and radiodestruction of solid tumors

P. Oh, Y. Li, J. Testa, E. Durr, K. Krasinska, P. Borgstrom, J.E. Schnitzer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 90 KB

english, 2004

18

8 The FDA perspective on marketing approval for anticancer agent

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

19

9 The EMEA perspective on marketing approval for anticancer agent

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

20

10 The industry perspective on marketing approval for anticancer agent

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

21

11 Overview of the models currently in development

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

22

12 Linking cancer genetics to cancer therapy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 273 KB

english, 2004

23

13 Patient and cell line derived human tumor xenograft models — preclinical/clinical correlations

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

24

14 Combined targeted agents with cytotoxic chemotherapy

L. Gianni, G. Bianchi, G. Mariani, S. Cresta

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

25

15 Radiation with targeted agents

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

26

16 Targeted agent with targeted agents

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 283 KB

english, 2004

27

18 US NCl perspective on tissue handling and banking

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

28

19 US cooperative group perspective on tissue handling and banking

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

29

20 Current challenges of national and pan European human tumour banking

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

30

21 Legal and ethical requirements of human tissue research

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

31

22 Human dendritic cell subsets and their implications for clinical studies

C.G. Figdor, J. de Vries, J. Lesterhuis, G.A. Adema, C. Punt

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

32

23 Development of heat shock cancer vaccine strategies

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

33

24 Experimental strategies to enhance the potency of dendritic cell-based cancer vaccines for clinical use

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 286 KB

english, 2004

34

25 Pharmaceutical industry, investigators and institutions: partners or tools? Practical issues in clinical cancer drug development. Erosion of the principal investigator in a climate of industry dominance

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 272 KB

english, 2004

35

26 The difficulties industry is experiencing with investigators

G.R.P. Blackledge

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 128 KB

english, 2004

36

27 Highlights from the 3rd EORTC-NCI International Conference on Cancer Molecular Markers: from discovery to clinical practice

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 128 KB

english, 2004

37

28 Molecular and clinical analysis of response to imatinib for locally advanced dermatofibrosarcoma protuberans

G. McArthur, G. Demetri, M. Heinrich, A. Van Oosterom, C. Corless, M. Debiec-Rychter, S. Dimitrijevic, Z. Nikolova, J. Fletcher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 136 KB

english, 2004

38

29 A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy

K.N. Chi, E. Eisenhauer, L. Fazli, E.C. Jones, J. Powers, A. Hurtado-Coll, S.L. Goldenberg, M.E. Gleave

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 136 KB

english, 2004

39

30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors

R.B. Cohen, N.J. Meropol, K.M. Padavic, N.L. Fox, A. Corey, M. Fleming, M. Mita, M. Hill, E.K. Rowinsky, A. Tolcher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 136 KB

english, 2004

40

31 Temozolomide (TMZ) targets only glioblastoma with a silenced MGMT-gene. Results of a translational companion study to EORTC 26981/NCIC CE.3 of radiotherapy ± TMZ

M. Hegi, A. Diserens, M. Hamou, T. Gorlia, M. Weller, J. Kros, J. Hainfellner, U. Bogdahn, G. Cairncross, R. Stupp

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

41

32 Functional analysis of PDK1 signalling pathway using knockout and knockin approaches; evaluation of PDK1 as a cancer target

D. Alessi, E. McManus, B. Collins, A. Mora

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

42

33 Approaches to inhibit the Akt pathway

W.R. Sellers, M. Meyerson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

43

34 Novel targets that control protein translation downstream from Akt and PTEN

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

44

35 Clinical experiences with mTOR inhibitors

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 273 KB

english, 2004

45

36 Transcriptional signature associated with sensitivity to ET-743 (Yondelis) in low passage sarcoma cell lines

M. Sanchez Beato, N. Martinez, I. Fernandez, M. Navarrete, P. de la Cueva, A. Carnero, J.C. Tercero, J. Jimeno, M.A. Piris

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 136 KB

english, 2004

46

37 Sensitivity and resistance of human leukemic blasts to aplidin; molecular signature by gene expression profiling (GEP)

N. Martinez, M. Sanchez Beato, G. Kaspers, I. Fernandez, P. de la Cueva, J.C. Tercero, J. Jimeno, M.A. Piris

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 136 KB

english, 2004

47

38 The role of sample preparation on gene expression profiling: impact on clinical use of microarray technology

S. Debey, U. Schoenbeck, T. Zander, J.L. Schultze

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 136 KB

english, 2004

48

39 Discovery and development of multiplex angiogenesis inhibitors that target EphB4: validation with a novel chemical-genetics based in vivo model

D. Qian, S. Srinivasa, S. Mitchell, L. Elkin, D. Pippin, J. Darrow, J. Di Paolo, R. DeSimone, X. Qian, M. Velleca

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 280 KB

english, 2004

49

40 RAD001 sensitizes tumor cells to cisplatin-induced apoptosis in an mTOR dependent manner by inhibition of p53-induced p21 protein expression

I. Beuvink, A. Boulay, S. Fumagalli, F. Zilbermann, S. Ruetz, T. O'Reilly, F. Natt, J. Hall, H. Lane, G. Thomas

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

50

41 A potential for combining the rapamycin derivative RAD001 (everolimus) with the EGF/ErbB2/VEGF receptor tyrosine kinase inhibitor AEE788 in human cancer

C. Stephan, S. Zumstein-Mecker, S. Gerboth, A. Boulay, S. Ruetz, N. Hynes, J. Baselga, H.A. Lane

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

51

42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC)

G.K. Abou-Alfa, S. Ricci, D. Amadori, A. Santoro, A. Figer, J. De Greve, J. Douillard, M. Moscovici, B. Schwartz, L.B. Saltz

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 293 KB

english, 2004

52

43 Proteasome inhibition activates a p38 MAPK-dependent anti-apoptotic program involving MKP-1 and Akt

R. Orlowski, G. Small, Y. Shi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

53

44 Selective small molecule inhibitors of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer

P. Scherle, J. Fridman, X. Liu, E. Caulder, M. Hansbury, Y. Li, W. Yao, K. Vaddi, R. Newton, S. Friedman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

54

45 Eukaryotic translation initiation factor elF-4E is consistently upregulated with human prostate cancer progression: inhibition by siRNA or ASO therapy suppresses CaP xenograft growth

J. Graff, B. Konicek, R. Lynch, K. Hanna, S. Bailey, A. McNulty, R. Goode, T. Vincent, E. Marcusson, J. Carter

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 292 KB

english, 2004

55

46 Biological testing of the tyrphostin tyrosine kinase inhibitor Adaphostin (NSC 680410) as a vascular endothelial growth factor secretion inhibitor in human and murine tumor cells and tumor-activated bone marrow stromal cells

E. Egilegor, L. Mendoza, N. Gallot, M. Valcárcel, M. Solaun, M. Hollingshead, E. Sausville, F. Vidal-Vanaclocha

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

56

47 CRx-026: discovery and clinical development of a syncretic anti-mitotic agent with significant anti-cancer activity

P.J. Elliott, M.S. Lee, M. Keegan, Y. Zhang, M.J. Nichols, A.A. Borisy, C.T. Keith

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

57

48 In vivo selection of vascular extravasating phage: novel means to isolate prostate tumor-homing peptides

S. Deutscher, M. Dickerson, L. Landon, C. Illy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 292 KB

english, 2004

58

49 DNA aptamers that recognize the MUC1 tumour marker

C. Fereira, S. Missailidis

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

59

50 Inhibition of histone deacetylase 2 increases apoptosis and P21 expression

S.C. Hooi, M.L. Laban, B.H. Huang, L. Lee, G.C. Raju, C.K. Lee, M. Salto-Tellez

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

60

52 Attenuated immunogenicity and toxicity of PEGylated recombinant methioninase (PEG-rMETase) in primates

Z. Yang, J. Wang, Y. Kobayashi, C. Lian, S. Li, X. Sun, Y. Tan, S. Yagi, E.P. Frenkel, R.M. Hoffman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 278 KB

english, 2004

61

53 Pyrrolo[3,4-c]carbazole-1,3-dione inhibitors of the G2/M checkpoint kinase wee1

B.D. Palmer, R.J. Booth, W.A. Denny, K. Hook, A.J. Kraker, H.H. Lee, D. Ortwine, J.B. Smaill, C. Squire, A.M. Thompson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

62

54 In vitro, in vivo and in silico examination of the activity of antitumor 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles

T. Bradshaw, C. Leong, M. Suggitt, D. Swaine, M. Bibby, M. Stevens

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

63

55 A phase I study of SB-715992, a novel kinesin spindle protein (KSP) inhibitor: pharmacokinetic (PK)/pharmacodynamic (PD) modeling of absolute neutrophil counts (ANC)

D. Williams, S. Kathman, Q. Chu, K. Holen, E. Rowinsky, G. Wilding, P. Mudd, J. Herendeen, J. Orr, L. Pandite

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 273 KB

english, 2004

64

56 Hsp90-targeted therapy for small cell lung cancer

G. Chiosis, N. Rosen, J. Kim, J. Aguirre, D. Solit, M. Vilenchik

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

65

57 The facilitative glucose transporter Glut-1 as a target for novel anti-cancer agents

A. Evans, S. Brittain-Dissont, K. Williams, I. Stratford, R. Airley

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

66

58 Pharmacodynamic responses to a novel histone deacetylase inhibitor, PXD101, in mice and humans

J.A. Plumb, N. Steele, T.R.J. Evans, P.W. Finn, P.B. Jensen, R. Kristeleit, J. DeBono, R. Brown

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

67

59 Comparison of the efficacy of MS-275, Cl-994 and SAHA in vivo in various experimental tumor models after oral application

H. Hess-Stumpp, D. Grossbach, P. Lienau

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 293 KB

english, 2004

68

60 Geldanamycin combined with bortezomib interferes with the ER-associated protein degradation function of valosin-containing protein

E. Mimnaugh, W. Xu, B. Scroggins, X. Yuan, T. Prince, S. Hartson, M. Vos, L. Neckers

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 155 KB

english, 2004

69

61 Mutant-PTEN leads to constitutive integrin-linked kinase (ILK) activity that regulates PKB/Akt activity in glioblastoma cancer cells and targeting ILK results in tumor growth-delay in vivo

L. Edwards, B. Thiessen, V. Dragowska, T. Daynard, S. Dedhar, M. Bally

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 155 KB

english, 2004

70

62 Isolation of pericytes from vasculature of human lung tumors

R. Bagley, C. Rouleau, S. Morgenbesser, B. Teicher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 301 KB

english, 2004

71

63 Identification of important genes for recurrence of gastric cancer by gene expression profiling

M. Motoori, I. Takemasa, M. Yano, H. Miyata, S. Takiguchi, Y. Fujiwara, T. Yasuda, Y. Kurokawa, K. Kato, M. Monden

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

72

64 Assessment of antitumor effects of erlotinib prior to first-line surgical treatment of head and neck squamous cell carcinoma

J.P. Delord, F. Thomas, I. Hennebelle, J. Sarini, A. Benlyazid, M. Rives, E. Chatelut, B. Allal, P. Rochaix

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

73

65 Kinomic profiling identifies PKC/Akt and beta-catenin/TCF mediated signal transduction as important targets of celecoxib in colon cancer

J.B. Tuynman, M.P. Peppelenbosch, E.M.J. Boon, A.H. Zwinderman, D.J. Richel

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

74

66 Anti-proliferative activity of a PPAR gamma agonist is associated with changes in the expression of cell cycle and apoptosis related genes in human ovarian cancer cells

S. Vignati, V. Albertini, A. Rinaldi, F. Bertoni, G. Carbone, C. Catapano

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 287 KB

english, 2004

75

67 Assessment of treatment efficacy in preclinical drug testing using magnetic resonance imaging

J.B. Moody, P. McConville, R.J. Lister, W.L. Elliott, B.A. Moffat, T.L. Chenevert, D.L. Dexter, A. Rehemtulla, B.D. Ross, W.R. Leopold, J.B. Moody

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

76

68 Spermine/spermidine N1-acetyltransferase: a new target for prevention and/or therapy of colorectal cancer

F.G. Berger, C. Davis, J.M. Tucker, D.L. Kramer, C.W. Porter

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

77

69 Essential role of inducible 6-phosphofructo-2-kinase in ras transformation

S. Telang, A. Yalcin, A. Clem, J. Chesney

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 282 KB

english, 2004

78

70 Therapeutic human monoclonal antibody targeting VEGFR-1 suppresses growth of human breast cancers

Y. Wu, Z. Zhong, H. Li, G. Makhoul, R. Bassi, P. Balderes, J. Tonra, D. Ludwig, P. Bohlen, D. Hicklin

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

79

71 In vivo efficacy of STI571 in xenografted human small cell cancer alone or combined with chemotherapy

D. Decaudin, P. de Cremoux, X. Sastre, F. Némati, C. Tran-Perennou, P. Fréneaux, A. Livartowski, P. Pouillart, M.F. Poupon

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

80

72 Restoration of wild-type p53 in malignant melanoma

D. Weber, J. Markowitz, A. MacKerell, F. Carrier

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

81

73 Inhibition of choline kinase is a highly specific and selective cytotoxic antitumoral strategy

M. Bañez-Coronel, A. Rodriguez-Gonzalez, A. Ramirez de Molina, A. Ramos, J.C. Lacal

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 279 KB

english, 2004

82

74 Determinants of the synergistic interaction between TS inhibitors, IFN-gamma and Fas signaling in therapy of colon cancer

J.A. Houghton, D.M. Tillman, L.S. Schwartzberg, J.I. Geller

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

83

75 Conjugates of lytic peptides target and destroy prostate cancer metastases

C. Leuschner, W. Hansel, F. Enright

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

84

76 ZD4054: assessment of endothelin A receptor specificity following single dose administration in healthy volunteers

C. Morris, D. Wilson, A. Hughes, F. Le Maulf, S. Brahma, R. Fuhr

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

85

77 MKP-1/CL 100 activity modulates cisplatin responses in non-small cell lung carcinoma

R. Perona, S. Chattopadhyay, C. Moratilla, C. Belda, P. Cejas, J. Fresno-Vara, R. Machado, M. Nistal, M. Gonzalez-Barón

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

86

78 ZD4054 specifically inhibits endothelin A receptor-mediated anti-apoptotic effects, but not endothelin B receptor-mediated pro-apoptotic effects

N. Curtis, Z. Howard, N. Brooks, J. Curwen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

87

79 Characterization of novel therapeutic receptor target candidates for treatment of small cell lung cancer

H.S. Poulsen, T.T. Poulsen, M.W. Pedersen, N. Pedersen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

88

80 Membrane gamma-glutamyltransferase as a target for intervention on several redox-modulated functions of the cancer cell

A. Pompella, A. Paolicchi, S. Dominici, A. Corti, M. Franzini, V. De Tata, E. Maellaro, R. Supino, F. Zunino, A. Casini

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 288 KB

english, 2004

89

81 Synergistic effects of Apo-2L/TRAIL and ionizing irradiation in human tumor cell lines without relevant damage of normal tissue cells

P. Marini, A. Schmid, H. Faltin, V. Jendrossek, W. Budach, C. Belka

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

90

82 MS-275, a potent orally active inhibitor of histone deacetylases is highly active in experimental tumor models of melanoma and prostate cancer

H. Hess-Stumpp, J. Hoffmann, A. Schott

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

91

83 Antitumor activities of MGCD0103, a novel isotype-selective histone deacetylase inhibitor

Z. Li, N. Zhou, M. Fournel, G. Rahil, J. Wang, D. Delorme, O. Moradei, R. MacLeod, J. Besterman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

92

84 Regulation of the oncogenic x-protein of hepatitis B by cellular chaperones

X. Yuan, W. Xu, L. Neckers

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 295 KB

english, 2004

93

85 Progenitor cells derived from human bone marrow contribute to the growth of breast cancer cells

R. Bagley, A. Dash, X. Cao, T. Lodie, S. Madden, R. Tubo, B. Teicher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

94

86 Preclinical pharmacokinetics (PK) and CNS distribution of RTA 203, a novel mammalian vacuolar H+-ATPase inhibitor

K. Culotta, N. Thapar, C. Meyer, D. Ferguson, J. Thapar, M. Johansen, T. Madden

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

95

87 Selection of pre-invasive lung cancer binding peptides using random phage display libraries

J.Y. Hung, A.J. Rebello, S. Lam, J.C. Ieriche

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

96

88 Substrate phage display: screening-approach for radiation-induced posttrasnlational peptide modifications in a complex proteome

A. Broggini-Tenzer, B. Hofstetter, C. Sauser, S. Bodis, P. Schubiger, C. Bonny, M. Pruschy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 297 KB

english, 2004

97

89 Gene expression profiling of cancer associated fibroblasts

P. Micke, C. Sundquist, D. Hägerstrand, S. Scheidl, P. Lindahl, F. Pontén, C.H. Heldin, A. Ostman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

98

90 AG879, a tyrphostin c-erbB-2 inhibitor, leads to transcriptional repression of cyclin D1 in pancreas cancer cells through a p27Kip1 independent pathway

A.N. Salesiotis, R. Samara, L. Laguinge, S. Ling, J.M. Jessup

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

99

91 17-allylamino-17-demethoxygeldanamycin overcomes trail resistance in colon cancer cell lines

I. Vasilevskaya, P. O'Dwyer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

100

92 A phase I, pharmacological and biological study of Sarasar® (Ionafarnib, SCH 66336), cisplatin and gemcitabine in patients with advanced solid tumors

L. Gore, M. Basche, S.N. Holden, C. O'Bryant, M.K. Schultz, S. Grolnic, M. Morrow, S.G. Eckhardt

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 295 KB

english, 2004

101

93 Genetic validation of activated polyamine catabolism as a novel therapeutic strategy targeting prostate cancer

C.W. Porter, K. Kee, D.L. Kramer, F.G. Berger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

102

94 The cytotoxic effects of 17-AAG, an inhibitor of Hsp90 are enhanced by combination with the PI-3-kinase inhibitor LY294002 in non-small cell lung cancer (NSCLC) cell lines

V. Papadimitrakopoulou, S. Angelaki, S. Lnu, E. Brown, G. Ayers

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

103

95 Expression of genes relevant for tumour aggressiveness in endometrial cancer

E. Steiner, J. Sagemüller, J. Brieger, C. Lindner, M. Werling, H. Kölbl

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 299 KB

english, 2004

104

96 Characterization of carbonic anhydrase 9 (CA9) overexpression: endogenous hypoxia marker and potential tumor-specific target

D. Vordermark, A. Katzer, A. Kaffer, S. Riedel, M. Flentje

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 155 KB

english, 2004

105

97 Eradication by induced apoptosis of chemoresistant infiltrating ductal carcinoma (IDC) characterised by HDAC2 overexpression and 5′CpG island hypermethylation of the FHIT, RARb2, BRCA1, APC, p16(CDKN2A), RASSF1A, CDH1(Ecadherin), stratifin, MDG1 and HIC1 oncosuppressor genes after combined treatment consisting of immunochemoconjugate of anti-DNMT1/HDAC2 bispecific F(ab)2-bsAb linked with cleavable disulfide onto vinorelbine (I-VRL)

J. Giannios, E. Michailakis, P. Lambrinos

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 155 KB

english, 2004

106

98 The role of NAD(P)H: quinone oxidoreductase 1 (NQO1) in geldanamycin, 17AAG and 17AG metabolism

D. Siegel, W. Guo, D. Gustafson, J. Zirrolli, D. Ross

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 298 KB

english, 2004

107

99 Para-amino benzoic acid (PABA) modulation of chemotherapy — evolution from preclinical work to a Phase I study. A report of early clinical activity including pharmacokinetic and pharmacodynamic studies

A. Pavlick, L. Liebes, F. Muggia, K. Farrell, J. Goldberg, S. Mendoza, D. Fry, M. Caunt, J. Roth, P. Brooks

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

108

100 A peptide inhibitor of t(4;11) leukemia

J. Nesbit, C.S. Hemenway

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

109

101 Combinatorial cancer therapy using a pharmacological inhibitor of indoleamine 2,3-dioxygenase (IDO), a target of the cancer suppression gene Bin1

A.J. Muller, J.B. DuHadaway, E. Sutanto-Ward, P.S. Donover, G.C. Prendergast

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

110

102 The synthetic lethal trap: a general approach for screening small-molecule protein inhibitors using genetic triangulation in the yeast Saccharomyces cerevisiae

D. Bellows, P. Jorgensen, M. Tyers, D. Bellows

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 292 KB

english, 2004

111

103 High-throughput screening against intractable targets: the use of target disruption gene signatures for rapid cancer drug discovery

P.E. Young, J. Castaneda, M. Chakiath, K. Evans, S.K. Horrigan, S. Pikul, M.J. Shea, D.R. Soppet, J.W. Strovel, Q. Zong

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

112

104 Novel drug discovery strategies based on aptamer inhibitors which are especially useful for orphan targets

M. Blind, G. Mayer, B. Bandilla, K. Klenzke, P. Rudolph, S. Fesele, A. Girod, M. Grättinger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

113

105 High throughput screening of a natural product library for telomerase inhibitory agents using target-defined model systems and bioinformatics

F. Dai, G. Kelter, S. Driever, T. Greiner, H.H. Fiebig, J.A. Double, A.M. Burger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

114

106 A highly efficient approach to the anticancer drug discovery of potent small molecule kinase inhibitors

J. Mendoza, J. Dickson, I. Popa-Burke, R. Mohney, J. Murray, C. Toole, L. Cheatham, P. Bernasconi, K. Williams, N. Hodge

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

115

107 Screening the DTP diversity set for compounds that inhibit the growth of human melanoma cells with defined mutations

A.J. Sakko, V.J.N. Bykov, K.G. Wiman, J. Hansson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

116

108 Profiling in vitro and in vivo of MS275, SAHA, LAQ824 and VPA as HDAC inhibitors currently tested in clinical trials

T. Beckers, C. Burkhardt, H. Wieland, J. Braunger, P. Gimmnich, T. Maier

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

117

109 Identification of small molecule inhibitors of PKB/AKT in a high throughput screen

W. Aherne, S. Burns, J. Travers, Y. Newbatt, M. Rowlands, D. Barford, I. Collins, N. Thompson, M. Garrett, P. Workman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 265 KB

english, 2004

118

110 In vitro screening of anticancer drug penetration into tumour tissue

A.H. Kyle, L.A. Huxham, A.I. Minchinton

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

119

111 Development and validation of a mass spectrometric assay to evaluate drug-drug interaction in human liver microsomes. Application to anticancer agents

F.I. Raynaud, J. Moreno-Farre, P. Workman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

120

112 Pharmacokinetic-pharmacodynamic (PK-PD) modeling of tumor growth inhibition in mice: a magnetic resonance imaging study

M. Rocchetti, A. De Grassi, M. Simeoni, E. Pesenti, M. Russo, I. Poggesi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

121

113 Pharmacokinetic-pharmacodynamic (PK-PD) modeling of tumor growth inhibition in mice: the activity of brostallicin is enhanced in cells with high glutathione-S-transferase

M. Germani, M. Rocchetti, M. Simeoni, F. Del Bene, E. Pesenti, C. Geroni, T. Colombo, S. Marchini, I. Poggesi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 128 KB

english, 2004

122

114 Cell lysate arrays — high performance protein profiling and signaling pathway mapping

M. Pawlak, E. Schick, P. Oroszlan, M. Ehrat

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 128 KB

english, 2004

123

115 A radioiodinated meta-iodobenzylguanidine-octreotate conjugate

G. Vaidyanathan, M.S. O'Dorisio, D.J. Affleck, P.C. Welsh, M.R. Zalutsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 253 KB

english, 2004

124

116 Inhibition of p53-MDM2 pathway by novel boronic-chalcones

A. Modzelewska, A. Geetha, M. Ghosh, C. Pettit, N.E. Davidson, T. Holak, P. Huang, S.R. Khan

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 126 KB

english, 2004

125

117 Identification of novel cyclin dependent kinase 1/2 inhibitors using fragment based high-throughput X-ray crystallography and structure based drug design

P.G. Wyatt, V. Berdini, M.G. Carr, J.E. Curry, D.J. Davis, M. O'Reilly, G. Saxty, M.S. Squires, A.J. Woodhead, A.J.-A. Woolford

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 126 KB

english, 2004

126

118 Substituted 7-amino-4-anilino-6-alkoxy-3-quinolinecarbonitriles as Src kinase inhibitors

H. Tsou, E. Overbeek-Klumpers, W. Hallett, J. Golas, F. Boschelli

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 126 KB

english, 2004

127

119 A novel strategy to inhibit Stat3 for human cancer therapy

N. Jing, Y. Li, W. Sha, W. Xiong, D. Tweardy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 264 KB

english, 2004

128

120 Synthesis and cytoxicity studies of platinum nucleobase adducts

A.R. Khokhar, M.S. Ali, Z.H. Siddik

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

129

121 Synthesis, anti-proliferative and anti-angiogenic effects of sulfamoylated 2-methoxyestradiol analogues

M.P. Leese, K. Gaukroger, J.J. Robinson, J.M. Day, S.P. Newman, S. Chander, A. Purohit, M.J. Reed, B.V.L. Potter

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

130

122 Identification of inhibitors of the MDM2-p53 interaction using a virtual screening approach with multiple binding modes

I.R. Hardcastle, S.U. Ahmed, S. Guyenne, C. Hutton, P. Kallblad, S. Kemp, J. Lunec, R. Reid, K. Saravanan, H.M.G. Willems

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 260 KB

english, 2004

131

123 Chemical and structural studies on thioredoxin-inhibitory antitumour quinols

A.D. Westwell, A.J. McCarroll, J.M. Berry, R. Ren, D.L. Rathbone, P.R. Lowe, C.H. Schwalbe, M. Burke, C.A. Laughton, M.F.G. Stevens

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 122 KB

english, 2004

132

124 Peptidomimetic inhibitors of Stat3: structure—activity relationships and cellular activity

J.S. McMurray, P.K. Mandal, D.R. Coleman, Z. Ren, X. Chen, W. Liao, N.J. Donato

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 122 KB

english, 2004

133

125 Synthesis, biological evaluation and structure activity relationships of a novel servies of aromatic hydroxamic acids as potent HDAC inhibitors

K. Van Emelen, J. Arts, P. Angibaud, H. De Winter, S. Van Brandt, M. Verdonck, J. Van Dun, T. Geerts, W. Floren, J. Van Gompel

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 250 KB

english, 2004

134

126 Development of a new series of tricyclic pyrimido-indole inhibitors targeting Aurora kinases

S.L. Warner, H. Vankayalapati, S. Bashyam, C.L. Grand, H. Han, D.D. Von Hoff, L.H. Hurley, D.J. Bearss

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 131 KB

english, 2004

135

127 Integrin receptor binding and cytotoxicity of cyclopeptides and their chlorambucil conjugates containing RGD or NGR sequence

H. Süli-Vargha, N. Mihala, R. Morandini, R.J. Kok, G. Ghanem

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 131 KB

english, 2004

136

128 Sapphyrins: structure-activity relationships in a novel series of potential anti-cancer agents

L. Naumovski, M. Sirisawad, P. Lecane, Z. Wang, L. Fu, D. Magda, P. Thiemann, G. Boswell, J. Ramos, R. Miller

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 260 KB

english, 2004

137

129 Biarylalanine inhibitors of histone deacetylase enhance radiation sensitivity in cancer cells

M. Jung, S. Schäfer, S. Wittich, A. Dritschilo, M. Jung

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 132 KB

english, 2004

138

130 Structural features of texaphyrin metal complexes leading to altered metal cation response in cancer cells

D. Magda, P. Lecane, C. Lepp, Z. Wang, R. Miller

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 132 KB

english, 2004

139

131 Pharmacodynamic analysis of apoptosis and anti-vascular activity in GIST patients treated with Imatinib

D. Davis, H. Choi, H. Macapinlac, P. Pisters, C. Charnsangavej, R. Benjamin, J. Abbruzzese, J. McConkey, J. Trent

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 273 KB

english, 2004

140

132 A phase I and pharmacokinetic clinical trial of subcutaneous (sc) VEGF trap in advanced solid tumor patients

J. Dupont, L. Schwartz, J. Koutcher, D.R. Spriggs, M.S. Gordon, D. Mendelson, J. Murren, A. Lucarelli, J.M. Cedarbaum

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

141

134 In vitro and in vivo characterization of exel-7647, a novel spectrum selective receptor tyrosine kinase inhibitor that modulates angiogenesis and tumor cell proliferation

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

142

133 A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer

N. Fernando, M. Morse, G. Blobe, L. Sutton, L. Odogwu, W. Honeycutt, M. Bauer, M. Mahon, Y. Daohai, H. Hurwitz

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

143

135 A clinical phase I dose escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study of BIBF 1120 in advanced cancer patients

K. Mross, F. Baas, M. Medinger, J. Drevs, R. Strecker, J. Hennig, M. Wolters, G. Stehle, M. Stefanic

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

144

138 Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by co-administration of non-steroidal anti-inflammatory drugs

B. Baguley, L.Cs. Wang, L.-M. Ching, J. Paxton, Q. Ding, P. Kestell

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 292 KB

english, 2004

145

139 BAY 57-9352: an inhibitor of VEGFR-2 and PDGFR receptor tyrosine kinases that demonstrates anti-angiogenic activity in vitro and in vivo

J. Elting, R. Jones, C. Carter, C. Flynn, G. Zhu, C. Damico, M. McHugh, B. Hibner, H. Kluender, S. Boyer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

146

140 A two-stage phase II study of the matrix metalloproteinase inhibitor (MMPI) Col-3 in patients with advanced soft tissue sarcoma (ASTS) — report of stage I data

K. Papadopoulos, Q. Chu, S. Syed, J. Curtright, G. Schwartz, M. Mita, E. Calvo, B. Forouzesh, A. Tolcher, E. Rowinsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

147

141 The spectrum-selective kinase inhibitor EXEL-0999 inhibits mitogenic and angiogenic kinases, and causes rapid tumor vasculature destruction and regression in mouse xenograft models

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

148

142 Impact of scheduling on combined ZD6474 and radiotherapy in head and neck tumor xenografts

D.L. Gustafson, A.L. Merz, J.A. Zirrolli, K.D. Connaghan-Jones, D. Raben

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 285 KB

english, 2004

149

143 The interferon-inducible GTPase MxA is a metastasis suppressor

J.F. Mushinski, P. Nguyen, C. Khanna, S. Lee, W.M. Linehan, M.-J. Lee, M.A. Horrisberger, A. Mendoza, E.J. Chung, J. Trepel

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

150

144 Develop novel cancer drug that controls angiogenesis factor expression post-transcriptionally

L. Cao, J. Bombard, S. Choi, H. Qi, N. Tamilarasu, E. Preston, J. Hedrick, T. Davis, M. Weetall, Y. Moon

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

151

145 A mitogenic-independent mechanism for ErbB receptor-induced tumour cell invasion

M. Alaoui-Jamali, H. Qiang, N. Benlimame, I. Dupre

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 286 KB

english, 2004

152

146 E7080, a novel multi-targeted tyrosine kinase inhibitor, exhibits anti-angiogenic activity via inhibition of KIT signalling in a small cell lung cancer xenograft model

J. Matsui, Y. Yamamoto, K. Miyazaki, A. Tsuruoka, T. Watanabe, M. Okada, S. Abe, T. Wakabayashi, M. Asada

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

153

147 Phase I pharmacokinetic (PK) and safety study of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2) in patients with solid tumors

M.E. Cianfrocca, J. Gallo, T. Cardoso, J.W. Lee, K.A. Kimmel, G. Hudes, N. Lewis, L. Weiner, R.B. Cohen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

154

148 BAY 57-9352: an inhibitor of VEGFR-2 and PDGFR receptor tyrosine kinases that demonstrates broad anti-tumor activity as a single agent in preclinical models

Y. Chang, C. Cortes, C. Brink, B. Polony, P. Vincent, D. Xue, D. Wilkie, A. McNabola, C. Carter, J. Elting

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

155

149 Inhibition of vasculogenic mimicry in melanoma by the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

L. Zhao, S. Edgar, E. Marshall, L. Kelland, B. Baguley

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 280 KB

english, 2004

156

150 Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer

H. Koeppen, W. Ince, E. Holmgren, M. Zhang, P. Tobin, R. Zhang, W. Novotny, K. Hillan

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

157

151 AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors

R. Herbst, R. Kurzrock, M. Parson, R. Benjamin, L. Chen, C. Ng, M. Ingram, S. Wong, D. Chang, L. Rosen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

158

152 A synthetic resveratrol analog inhibits the proangiogenic response of liver sinusoidal cells to tumor-derived factors during hepatic melanoma metastasis formation

O. Elvira, S. Clarisa, G. Natalia, L. Aritz, P.C. Fernando, V. Fernando

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 277 KB

english, 2004

159

153 Inhibition of cytosolic superoxide dismutase (SOD1) in endothelial cells: a possible mechanism for the antiangiogenic properties of the copper depleting drug ATN-224

O. Betancourt, F. Donate, X. Guan, D. Shaw, A. Mazar, S. Pirie-Shepherd

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

160

154 The VEGFR-2 tyrosine kinase inhibitor, ZD6474, enhances the

D. Siemann, W. Shi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

161

155 PTK787/ZK 222584 (PTK/ZK), a potent orally active and highly selective inhibitor of VEGFR kinases, is highly efficacious in various experimental tumor models either as mono- or combination therapy

H. Hess-Stumpp, M. Haberey, A. Reichel, K.H. Thierauch

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

162

156 A phase I dose-escalation study with oral LY317615 (L) in combination with capecitabine (C) in advanced cancer patients

S. Holden, C. Britten, D. Prager, R. Finn, M. Le, M. Basche, C. O'Bryant, A. Levin, D. Thornton, S. Eckhardt

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

163

157 Phase I trial of an antisense to vascular endothelial growth factor (VEGF-AS, Veglin) in relapsed and refractory malignancies

D.I. Quinn, A.M. Levine, G. Gorospe, H.J. Lenz, A. Mohrbacher, J.S. Weber, S. Iqbal, P. Gill, A. Tupule

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

164

158 BIBF1120 a novel, small molecule triple angiokinase inhibitor: profiling as a clinical candidate for cancer therapy

F. Hilberg, U. Tontsch-Grunt, F. Colbatzky, A. Heckel, R. Lotz, J.C.A. van Meel, G.J. Roth

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

165

159 Blocking VEGF and EGF receptor signaling with ZD6474 sensitizes human non-small cell lung cancer to chemotherapy with paclitaxel

W. Wu, T. Shintani, M.S. O'Reilly, R.S. Herbst

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 289 KB

english, 2004

166

160 Antitumor therapy with VEGF receptor tyrosine kinase inhibitor ZD6474 in a mouse model of intestinal cancer

R.A. Goodlad, A. Ryan, J. Watson, S.R. Wedge, I.T. Pyrah, N. Mandir, R.W. Wilkinson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

167

161 Anticancer effects of ZD6474 in gefitinib (Iressa™)-resistant lung cancer cell lines in vitro

B. Helfrich, T. Troiani, D. Raben, B. Frederick, D. Gustafson, A. Merz, S. Weed, P. Bunn

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

168

162 In vivo effects of a monoclonal antibody to the murine VEGFR-3 that antagonizes the binding of VEGF-C and receptor signaling

K. Persaud, J. Goldman, M. Prewett, J. Tonra, R. Bassi, D. Anderson, D. Hicklin, L. Witte, M.A. Swartz, B. Pytowski

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

169

163 Fluorescent imaging of tumor growth, angiogenesis, metastasis and apoptosis using transplantable syngeneic models of murine neuroblastoma

J. Wigginton, J. Hixon, T. Back, E. Lincoln, T. Khan, R. Salcedo, J. Stauffer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

170

164 Targeting oncogenic Eph proteins with Hsp90 inhibitors

J.S. Isaacs, L. Neckers

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

171

165 AZD2171, a potent VEGF receptor tyrosine kinase inhibitor, combined with mechanistically distinct antitumor therapies in vivo

S. Wedge, J. Kendrew, P.J. Valentine, S.R. Brave, S. Barnett, J.M. Jurgensmeier, L.F. Hennequin, D.J. Ogilvie

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

172

166 A phase I dose-escalation study of anti-a5β1 integrin monoclonal antibody (M200) in patients with refractory solid tumors

A. Ricart, G. Liu, A. Tolcher, G. Schwartz, J. Harris, R. Stagg, E. Rowinsky, G. Wilding

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 297 KB

english, 2004

173

167 Combination with PI3 kinase inhibitors allows drastic dose reduction of tumor necrosis factor

P. Brouckaert, L. Huyghe, A. Goethals, J. Hostens, M. Van den Hemel

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

174

168 PRL-3 promotes invasion in tumor epithelial cells and tube formation in normal endothelial cells

C. Rouleau, L. Kurtzberg, T.St. Martin, M. Dufault, A. Roy, P. Boutin, J. Pinkas, M. Nacht, S. Madden, B.A. Teicher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

175

169 Maximizing the anti-tumor and anti-proliferative effects of 2ME2 by maintaining levels above a threshold concentration for a defined period of time

A. Treston, G. Swartz, B. Chen, A. Hanson, W. Smith, K. Volker, S. Plum, C. Sidor, W. Fogler, U. Klein

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 299 KB

english, 2004

176

170 A6, a urokinase plasminogen activator (uPA)-derived peptide: a phase I trial in patients with advanced gynecologic cancer

A. Berkenblit, M.A. Gold, U.A. Matulonis, J.F. Kroener, B.J. Dezube, G.N. Lam, N. Brünner, T.R. Jones, M.H. Silverman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

177

171 Unnatural small molecule mimic of VLA-4-binding VCAM-1 epitope inhibits the intravascular adhesion and proliferation of metastatic melanoma cells

M. Lorea, Z. Aizpea, C. Teresa, V. Silvia, V. María, A. Mirari, A. Ana, P.C. Fernando, V. Fernando

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

178

172 Preclinical profile of ABP309, a potent 2nd generation VEGF receptor tyrosine kinase inhibitor belonging to the class of aminonicotinamides

J. Brueggen, G. Bold, R. Cozens, P.W. Manley, J. Mestan, C. Schnell, J.M. Wood

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 297 KB

english, 2004

179

173 Prostate specific membrane antigen (PSMA) expression in the neo-vasculature of non-prostate cancers: in vitro target validation and in vivo imaging

J. Ross, C. Sheehan, D. Schenkein, I. Webb, G. Gray

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

180

174 Correlation between protein kinase C-beta expression and patient survivals in primary tumors — implications for clinical drug development

D. Li, M. Phong, M. Lahn, D. Thornton, L. Brail, G. Ganji, B. Liao

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

181

175 Pseudolarix acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteosome-mediated degradation

M. Li, Z. Miao, W. Tan, J. Yue, C. Zhang, L. Lin, X. Zhang, J. Ding

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

182

176 In vitro human metabolism of BAY 57-9352: a novel VEGFR-2/PDGFR kinase inhibitor

S. Walle, M. Radtke, A. Kern, K. Schmeer, D. Seidel, P. Adams

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 295 KB

english, 2004

183

177 Tyrosine kinase inhibition as a strategy to suppress growth of primitive endothelial cells

V. MacDonald, E.B. Dickerson, N. Akhtar, J.F. Modiano, S.C. Helfand

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

184

178 Toxin-VEGF fusion protein inhibits tumor growth

T. Hu, C. Hamby, J. Backer, M. Backer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

185

179 Augmentation of radiation response in upper aero-digestive tract tumors with the vascular targeting agent ZD6126

T. Hoang, S. Huang, E. Armstrong, P. Harari

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 292 KB

english, 2004

186

180 Low-dose metronomic cyclophosphamide induced sustained hypoxia in human tumor xenografts, which can be exploited therapeutically by the combination with the hypoxic cell cytotoxin tirapazamine

U. Emmenegger, G.C. Morton, G. Francia, M. Franco, S. Man, R.S. Kerbel

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

187

181 Suppression of neuroblastoma by targeted delivery of interleukin-12 to tumor vasculature

E.B. Dickerson, N. Akhtar, Z.C. Neal, P.M. Sondel, S.C. Helfand

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

188

182 Effect of chemotherapy on human tumor xenografts differently expressing vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2)

M. Passiu, D. Coltrini, A. Garofalo, R. Dossi, M. Zucchetti, M. Presta, R. Giavazzi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

189

183 Gene delivery of Escherichia coli nitroreductase into endothelial cells prolongs the survival of tumor-bearing mice after the treatment with the prodrug CB1954

B.M. Colombo, M. Benouchan, F. Do Nascimento, C. Rocca, G.Y. Perret

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 275 KB

english, 2004

190

184 Pharmacokinetics of CNTO 328 in a three month intravenous dose toxicity study in cynomolgus monkeys with concomitant IL-2 therapy

Q. Jiao, U. Prabhakar, M. Frigo, T. Lohr, J. Cornacoff, H. Davis, M. Graham

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 133 KB

english, 2004

191

185 Phage display-derived peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-mediated cancer cell adhesion

S. Deutscher, L. Landon, V. Glinsky, J. Zou

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 133 KB

english, 2004

192

186 Potent analogues of the antiangiogenic agent NM-3 have enhanced antiproliferative activity in vitro

D. Masson, L. Nguyen, H. Phan, O. Maurhofer, H. Eschenhof, I. Flores-Montes, C. Severi, J.-L. Thuillard, C. Bentzen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 133 KB

english, 2004

193

187 Is hypoxia relevant in modulating the effects of the novel antiangiogenic agent, ZD6474, in head and neck cancer?

B. Frederick, B. Helfrich, D. Raben

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

194

188 Targeted delivery of endostatin using an antibody-endostatin fusion protein resulted in enhanced inhibition of tumor growth

S. Shin, H. Cho, M. Iruela-Arispe, S. Morrison, K. Webster, J. Rosenblatt

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

195

189 Rodent pharmacokinetics and antiangiogenic activity of a pyrimidopyrimidine dual KDR/FGFR antagonist

M. Simcox, B. Higgins, L. McDermott, T. Nevins, K. Kolinsky, M. Smith, H. Yang, J. Li, Y. Chen, K. Luk

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

196

190 Adaphostin (NSC680410) down regulates VEGF expression in human umbilical vein endothelial cells under hypoxia

G. Kaur, M. Hollingshead, K. Fisher-Nielsen, J. Zalek, K. Bonomi, S. Borgel, J. Thaillainathan, B. Uranchimeg, G. Melillo, E. Sausville

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

197

191 Recombinant endostatin prevents integrin alpha4, beta1-mediated adhesion and proliferation of vascular endothelial growth factor receptor-expressing B16 melanoma cells; antimetastatic implications

M. Valcárcel, L. Mendoza, T. Carrascal, E. Egilegor, F. Vidal-Vanaclocha

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

198

192 Transplanted hair follicles give rise to blood vessels in skin visualized in nestin-driven GFP mice

Y. Amoh, L. Li, M. Yang, P. Jiang, K. Katsuoka, A.R. Moossa, R.M. Hoffman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

199

193 Histone deacetylase inhibitors LAQ824 and LBH589 inhibit proliferation and modulate angiogenesis-related genes in human endothelial cells

D. Qian, P. Atadja, R. Pili

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

200

194 BARD1 catalyzes of p53 phosphorylation by DNA-damage response kinase and reverses malignant phenotype of ovarian cancer cells

I. Irminger-Finger, A. Feki, C. Jefford, P. Berardi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

201

195 Treatment of new cases of acute promyelocytic leukaemia by arsenic trioxide

A. Ghavamzadeh, K. Alimoghaddam, S. Rostami, H. Ghafari, M. Jahani, R. Hosseini, A. Mosavi, M. Irvani, B. Bahar, A. Khodabandeh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

202

196 Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumour disease

P. Grabowski, S. Griß, C. Arnold, D. Hörsch, R. Göke, R. Arnold, B. Heine, H. Stein, M. Zeitz, H. Scherübl

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

203

197 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-alpha related apoptosis inducing ligand receptor 2 (TRAIL R2) in patients with advanced cancer

J. de Bono, G. Attard, R. Plummer, S. Pacey, C. Bale, L. Vidal, A. Greystoke, N. Fox, A. Corey, H. Calvert

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

204

198 BARD1 required for telomere maintenance and control of genomic stability

I. Irminger-Finger, C. Jefford, I. Bondarew, S. Gagos, F. Callabrio, M. Saw, S. Chang

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 276 KB

english, 2004

205

199 Both RIP and c-FLIP are required for inhibition of caspase-8 cleavage in TRAIL-DISC in human cancer cells

J.H. Song, D.K. Song, N.M. Kneteman, C. Hao

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

206

200 Mutant p53 reactivation by PRIMA-1: a novel strategy for cancer therapy

K. Wiman, V. Bykov, N. Issaeva, N. Zache, J. Bergman, G. Selivanova

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

207

201 Analysis of survivin splice variant transcripts in human breast tumor cells

S. Lizard-Nacol, F. Vegran, R. Boidot, C. Qudin, B. Coudert

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

208

202 The proteasome inhibitor bortezomib (VELCADE™) sensitizes human tumor cells to TRAIL-mediated apoptosis by reduction of c-FLIP

T.J. Sayers, A.D. Brooks, J. Onksen, P.J. Elliott, W.J. Murphy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 285 KB

english, 2004

209

203 Modulation of DNA damage induced apoptosis by the proteasome inhibitor bortezomib (PS) in human colorectal and non-small cell lung cancer cells is p53-dependent and NK-kB-independent

N. Takigawa, S.A.J. Vaziri, T. Mekhail, D.R. Grabowski, K. Chikamori, J.E. Hill, A.V. Gudkov, R.M. Bukowski, R. Ganapathi, M.K. Ganapathi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

210

204 HGS-TR2J, a human, agonistic, TRAIL receptor 2 monoclonal antibody, induces apoptosis, tumor regression and growth inhibition as a single agent in diverse human solid tumor cell lines

R. Humphreys, L. Shepard, C. Poortman, E. Shields, R. Johnson, D. Gillotte, X. Huang, V. Albert

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

211

205 Erucylphosphocholine: molecular requirements for apoptosis induction by a membrane targeted drug

R. Handrick, J. Rudner, I. Müller, H. Eibl, C. Belka, V. Jendrossek

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

212

206 Defective Bim induction, downstream of glucocorticoid receptor nuclear translocation, in dexamethasone-resistant childhood acute lymphoblastic leukemia xenografts

R. Lock, P. Bachmann, R. Gorman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

213

207 Activation of the P73-P53AIP1 apoptotic pathway in leukemia cells by combining arsenic trioxide (ATO) with MEK1 inhibitor

P. Lunghi, A. Costanzo, M. Levrero, A. Bonati

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

214

208 HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase I trial

S.J. Hotte, A.M. Oza, L.H. Le, M. MacLean, A. Iacobucci, A. Corey, N.L. Fox, H.W. Hirte

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

215

209 Phase I clinical trial in patients with refractory solid tumors: the weekly 24 hour intravenous infusion of aviscumine, a recombinant ribosome-inactivating protein

P. Schöffski, I. Breidenbach, O. Bolte, M. Stadler, S. Zilz, K. Wilhelm-Ogunbiyi, H. Lentzen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 294 KB

english, 2004

216

210 Induction of apoptosis in chronic lymphocytic leukaemia by inhibition of NF-kB and novel sulfasalazine analogues

G. Packham, F. Habens, S. de Mel, N. Srinivasan, F. Oakley, D. Mann, K. Potter, F. Stevenson, A. Ganesan

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

217

211 BRCA1 functions as a differential modulator of chemotherapy induced apoptosis

J.E. Quinn, R.D. Kennedy, P.B. Mullan, P.G. Johnston, D.P. Harkin

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

218

212 Nuclear factor-kB activation in human gastric cancer: its correlation with clinicopathologic features and prognosis

S.Y. Nam, H.S. Lee, W.H. Kim, B.L. Lee

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

219

213 von Hippel-Lindau (VHL) and p53 dependent cytotoxic effects of the proteasome inhibitor bortezomib (PS) in human renal cancer cells

S.A.J. Vaziri, T. Mekhail, J.E. Hill, A.V. Gudkov, M.K. Ganapathi, R.M. Bukowski, R. Ganapathi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 280 KB

english, 2004

220

214 Deregulated expression of BARD1 in human tumors; a novel diagnostic and prognostic marker

I. Irminger-Finger, J. Wu, A. Vlastos, M. Pelte, A. Bianco, G. Laurent

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

221

215 High quality gene expression microarray data from the EORTC 10994/BIG 00-01 breast cancer study

P. Farmer, V. Becette, M. Tubiana-Hulin, P. Fumoleau, M. Piccart, L. Mauriac, J. Bergh, M. De Vos, R. Iggo, H. Bonnefoi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

222

216 SPC-2004 — a potent locked nucleic acid drug against Bcl-2 in cancer

B. Hansen, M. Westergaard, C.A. Thrue, M. Asklund, H. Oerum, M. Frieden

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

223

217 Srp20, the first transcriptionally up-regulated gene by flavopiridol (flavo), is a pre-mRNA splicing factor that induces apoptosis in human colon cancer cells

M. Motwani, P. Sridhar, G.K. Schwartz

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

224

218 A phase I and pharmacokinetic trial ARQ 501, an Activated Checkpoint Therapy (TM) agent, in patients with advanced solid tumors

A. Craig, G. Shapiro, D. Ryan, J. Eder, J. Supko, A. Wolanski, S. Jones, E. Regan, T. Bell, C. Li

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

225

219 FasL, but not TRAIL, induces apoptosis in human hepatocytes in chimeric mice

C. Hao, J.H. Song, B. Hsi, J. Levis, D.K. Song, K.C. Petruk, D.L.J. Tyrrell, N.M. Kneteman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

226

220 Identification of the molecular target for MX2167, a novel anticancer agent

S. Kasibhatla, K. Jessen, S. Maliartchouk, J. Wang, N. English, J. Drewe, H. Zhang, N. Sirisoma, S. Cai, B. Tseng

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 293 KB

english, 2004

227

221 Ceramide promotes JNK translocation and Bim phosphorylation in lung cancer derived A549 cells

P.P. Ruvolo, S.M. Kurinna, A.F. Nica, C.C. Tsao, T. Jiffar

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

228

222 P53-mediated apoptosis induced by NCX 4040, a nitric oxide-releasing aspirin derivative, in human colon cancer cell lines

A. Tesei, P. Ulivi, F. Fabbri, C. Leonetti, M. Scarsella, G. Zupi, D. Amadori, M. Bolla, W. Zoli

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

229

223 Evaluation of 2 new Rhodium ferrocene complexes for cytotoxicity, and apoptotic propensity to invoke alternative cell death pathways in prostate tumour cell lines

L. Bohm, C. van Rensburg, J. Swarts

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

230

224 Two distinct pathways regulate Bak function in apoptosis: a requirement for JNK1 in Bak 80–170 kDa complex formation but not in Bak activation

M. Shoshan, L. Strandberg Ihrlund, K. Viktorsson, G. Barna, K. Sabapathy, S. Linder

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 280 KB

english, 2004

231

225 Variable distribution of TRAIL Receptor 1 in primary human tumor and normal tissues

W. Halpern, C. Lincoln, A. Sharifi, C. Roach, J. Askaa, A. Klein-Szanto, R. Cohen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

232

226 Sulphamoylated 2-substituted oestrogens induce apoptosis through G2-M checkpoint arrest

Y. Ho, S.P. Newman, A. Purohit, M.P. Leese, B.V.L. Potter, M.J. Reed

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

233

227 NF-kappa-B: a differential modulator of chemotherapy induced apoptosis

J.W. Purcell, C. Finnegan, M. Thomas, K.M.A. Rogers, P.G. Johnson, M. Boland

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

234

228 A phase I trial of LY573636 in patients with advanced solid tumors

G. Simon, M. Sovak, M. Wagner, E. Haura, S. Gerst, D. deAlwis, G. Bepler, D. Sullivan, A. Weitzman, D. Spriggs

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

235

229 Activation of caspases in human t-lineage leukemia cells treated with analogs of leflunomide metabolite

A. Vassilev, Y. Zheng, O.O. Grigoriants, S. Qazi, F.M. Uckun

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

236

230 Roles of N-cadherin in anoikis and invasion

K. Hyeonseok, C. Hyeyeon, K. Wooseok, S. Soonah, K. Kunhong

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

237

231 Significance of radiation apoptosis in cancer and its modification by beta carotene

R. Sisodia, P. Srivastava, K.K. Nandchahal, A.L. Bhatia

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

238

232 In vitro and in vivo antitumor efficacy of NCX-4040, a nitric oxide-releasing non-steroidal anti-inflammatory drug, in combination with antineoplastic drugs on human colon cancer lines

C. Leonetti, M. Scarsella, G. Zupi, W. Zoli, D. Amadori, P. Ulivi, F. Fabbri, M. Bolla, R. Maucci, A. Tesei

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

239

233 Activation of NFkB pathway in diffuse large B-cell lymphoma

A.I. Sáez Castillo, M.J. Artiga, A. Perez-Rosado, F. Nogales, M. Piris

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

240

234 Induction of cell death by imidazoacridinone derivative C-1311 in T lymphoblastoid leukemia MOLT4 cells

A. Skwarska, E. Augustin, J. Konopa

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

241

235 Rapid activation of caspases involving microtubule stabilization and p53 upregulation by D501036, a novel selenophene derivative active against human renal cancer cells

T. Chen, S. Juang, Y. Li, C. Huang, P. Hsu, S. Chen, J. Chang, P. Hong, W. Hseih, C. Chang

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

242

236 PTTG/securin induces and modulates p53 expression and function

S. Kakar, T. Hamid

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 51 KB

english, 2004

243

237 PTEN regulates differential Fas apoptosis in Type I and Type II cells

J. Peacock, E. Pietras, M. Peter, C. Ong

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 51 KB

english, 2004

244

238 Oncogenic aberrations of SCF ubiquitin ligases

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 128 KB

english, 2004

245

239 The proteasome and proteasome pathway inhibitors in cancer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 128 KB

english, 2004

246

240 Hsp90 and molecular chaperones as targets in cancer therapy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 128 KB

english, 2004

247

241 Targeting the myeloma cell in its bone marrow microenvironment

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 128 KB

english, 2004

248

242 Imaging hypoxia in tumours

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 128 KB

english, 2004

249

243 Clinical significance of tumour hypoxia

M. Nordsmark, J. Eriksen, M. Horsman, J. Alsner, J. Overgaard

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 272 KB

english, 2004

250

244 Kidney cancer and the von Hippel-Lindau tumor suppressor protein: implications for therapy

W.G. Kaelin Jr, W. Kim, S. Lee, A. Reddy, M. Safran, Q. Yan, H. Yang

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

251

245 HIF-1, hypoxia inducible factor-1 as a therapeutic target

I. Stratford, R. Cowen, K. Williams

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

252

246 Novel ATP-competitive Akt inhibitors slow the progression of tumors in vivo

V. Giranda, Y. Luo, Q. Li, A. Shoemaker, R. de Jong, X. Liu, E. Han, K. Woods, S. Thomas, S. Rosenberg

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 284 KB

english, 2004

253

247 Silencing of survivin gene by small interfering RNAs (siRNAs) induces apoptosis in human prostate cancer cells and increases their sensitivity to 17-allylamino-17-demethoxygeldanamycin (17AAG)

F. Paduano, R. Villa, M. Binda, M. Folini, M. Pennati, M.G. Daidone, N. Zaffaroni

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

254

248 Antitumor activity, pharmacodynamics and toxicity of PX-866 a novel inhibitor of phosphoinositide-3-kinase

L. Kirkpatrick, G. Powis, N. Ihle, G. Paine-Murrieta, D. Minion, R. Halter, R. Abraham, P. Wipf

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

255

249 Novel small molecule inhibitors of 3′-phosphoinositide-dependent kinase-1 (PDK-1)

R.I. Feldman, J.M. Wu, M. Polokoff, D. Zhu, S. Biroc, B. Alicke, S. Yuan, B. Buckman, Z. Chang, D. Arnaiz

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

256

250 Modification of the histone code: effects of DNA methylation

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

257

251 Histone deacetylase inhibition — a promising anticancer therapeutic strategy

P. Atadja, M. Hsu, P. Kwon, R. Pili, K. Bhalla, A. Wood

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

258

252 Promising combinations of HDAC inhibitors and other agents

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

259

253 Clinical development of histone deacetylase inhibitors

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

260

254 Frequencies of tetramer+ T cells specific for HPV16 E7 epitopes in the circulation of patients with squamous cell carcinoma of the oropharynx

C. Arsov, K. Schirlau, M. Bas, U. Friebe-Hoffmann, T.L. Whiteside, H. Bier, T.K. Hoffmann

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

261

255 MVA-MUC1-IL2 vaccine immunotherapy for advanced non-small cell lung cancer (NSCLC): interim phase II data

N. Faivre-Bizouarne, T. Velu, B. Mennecier, M. Pless, V. Morel, E. Levy, V. Richard, J.M. Limacher, P. Squiban, E. Quoix

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

262

256 Structural mimics of heat shock protein70 (Hsp70) associated peptides from breast tumour cells can prime T cells to respond to tumour antigens

B. Arnaiz, L. Madrigal, D. Doherty, T.C. James, U. Bond

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

263

257 Genetic immunization against ratHER2/neu in tumor challenge and spontaneous mouse tumor mode

P. Gallo, S. Dharmapuri, M. Nuzzo, D. Maldini, B. Cipriani, G. Forni, P. Monaci

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 280 KB

english, 2004

264

258 A phase I trial in patients with solid tumours using autologous dendritic cells loaded with mannan-conjugated recombinant MUC1 protein

B.E. Loveland, A. Zhao, X.-P. Xing, B. Bardsley, S. France, J. Desai, C. Smith, V. Apostolopoulos, I.F.C. McKenzie, P.L. Mitchell

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

265

259 Induction of anti-tumor immunity by an anti-idiotype antibody mimicking human HER2/Neu

M. Chatterjee, K. Mohanty, S. Pal, A. Saha, K.A. Foon, S.K. Chatterjee

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

266

260 Allogeneic whole cell vaccination significantly delays disease progression in hormone-relapsed prostate cancer: final data from a phase II study

A. Michael, N. Quatan, N. Russell, F. Wushishi, J. Whelan, M. Whelan, H. Pandha

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

267

261 Multi-epitope peptide vaccine and co-administration of IL-12 prevents tumor growth in Her-2 transgenic mice

J. Jasinska, S. Wagner, H. Breiteneder, H. Pehamberger, O. Scheiner, C.C. Zielinski, U. Wiedermann

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 283 KB

english, 2004

268

262 Immunization with genetic vectors expressing rhesus CEA efficiently breaks immune tolerance in mice and rhesus monkeys

L. Aurisicchio, C. Mennuni, F. Calvaruso, M. Nuzzo, P. Giannetti, B. Cipriani, F. Palombo, P. Monaci, G. Ciliberto, N. La Monica

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

269

263 Synergistic antitumor activity of interleukin 23 and interleukin 2

C. Lo, P. Wu, S. Tang, M. Tao

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

270

264 Strong Melan-A/MART-1 specific CD8+ T cell responses to peptide vaccination in young melanoma patients

D. Speiser, D. Lienard, V. Rubio-Godoy, E. Devevre, A.M. Krieg, J.-C. Cerottini, P. Romero

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

271

265 First clinical evidences of antigen spreading in metastatic melanoma patients treated with a NGcGM3/VSSP/Montanide ISA 51 vaccine: a phase I/IIb study

G. Saurez, M. Osorio, E. Rodriguez, A. Carr, L. Anazagasti, M.C. Arango, A. Torrella, J. González, R. Pérez, L. Fernández

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 281 KB

english, 2004

272

266 Biological characterisation of CD40-activated B cells as cellular adjuvant in cancer vaccines

M. von Bergwelt-Baildon, B. Maecker, F. Fiore, L. Nadler, J. Schultze

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

273

267 Pharmacokinetics and pharmacodynamics of recombinant human IL-18 (rhIL-18) in patients with solid tumors

K.M. Koch, D. Kwok, T. McIntosh, P. Godillot, L. Rykaczewski, T.M. Conway, E. Leonard, E. Srour, D. Panka, M.M. Dar

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

274

268 P43/endothelial monocyte-activating polypeptide-II: protein exaptation provides a novel counterattack mechanism in colorectal tumours

J.C. Murray, P. Symonds, Y. Heng

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

275

269 Selective in vivo therapeutic targeting of prostate cancer with a specific double-amino-acid auxotroph of Salmonella typhimurium

M. Zhao, X.-M. Li, M. Yang, P. Jiang, R.M. Hoffman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

276

270 The relationship of hypoxia and erythropoetin to schwannoma protein and message expression and cellular proliferation: an opportunity for tumor cell functional and growth inhibition

J. Olson, Z. Zhang, D. Mattox

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

277

271 Phase II Study of Thalidomide, interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (RCC)

R. Amato, J. Brown, A. Rawat

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

278

272 Bone-targeted therapy for androgen-independent prostate cancer (AIPCa)

R. Amato, J. Brown, H. Henary

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 294 KB

english, 2004

279

273 Tissue lysate arrays as a cell based assay for validation of signal transduction inhibitors

Y. Lu, Q. Yu, H. Hall, S. Yu, R. LaPushin, T.S. Daynard, G. Mills

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

280

274 Insulin-like growth factor-binding protein 3: single-agent and synergistic effects with paclitaxel in breast tumour models

Q. Yu, L. Jerome, V. Page, K. Banerjee, L. Shiry, B. Leyland-Jones

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

281

275 Interleukin-12 inhibits AKT phosphorylation and upregulates cleavage and subcellular translocation of EGFP-bid within murine neuroblastoma tumors

J. Wigginton, J. Hixon, J. Stauffer, E. Lincoln, T. Back, J. Brenner, S. Lockett, K. Nagashima, T. Khan

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

282

276 Phase I trial of low dose interferon-alpha (IFN), thalidomide with gemcitabine and capecitabine in patients with progressive metastatic renal cell carcinoma (RCC)

R. Amato, N. Thompson, F. Naveed

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 276 KB

english, 2004

283

277 Analysis of c-kit expression in small cell lung cancer patients and its clinical implications

R. Sirera, M. Martin, P. Bayo, A. Blasco, M.J. Safont, C. Caballero, M. Martorell, C. Camps

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

284

278 Immunoassay and mass spectrometry analysis of specific EGFr phospho-tyrosines; effects of panitumumab (ABX: EGF), a fully humanized anti-EGFr monoclonal antibody, and the kinase inhibitor AG1478

D. Cerretti, C. Kozlosky, L. Guo, R. Miller, R. Johnson, R. Radinsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

285

279 Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

E. Van Cutsem, R.J. Mayer, P. Gold, P. Stella, A. Cohn, A. Pippas, P. Windt, P. Molloy, H.J. Lenz

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 271 KB

english, 2004

286

280 Updated results of the phase I study of SS1(dsFv)PE38 for targeted therapy of mesothelin expressing cancers

R. Hassan, S. Bullock, H. Kindler, I. Pastan

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

287

281 Phase I study of intravenous (IV) CI-1033 in patients with advanced solid tumors

G. Simon, S. Olson, M. Langevin, I. Eiseman, J. Mahany, W. Helmke, C. Garrett, R. Lush, P. Lenehan, D. Sullivan

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

288

282 Use of the humanized anti-EGFR antibody h-R3 and radiotherapy for the treatment of patients with high-grade astrocytic tumors

T. Crombet, J. Figueredo, M. Catalá, S. González, J. Selva, C. Toledo, O. Torres, R. Pérez, A. Lage

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 290 KB

english, 2004

289

283 Targeting of human glioma xenografts with an anti-EGFRvIII minibody (MR1-1scFv-CH3)

C. Kuan, G. Vaidyanathan, M.R. Zalutsky, I. Pastan, D.D. Bigner

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

290

284 Effects of erlotinib on HER2/HER3 receptor activation and downstream signaling events in cells lacking EGFR expression

G. Schaefer, K. Totpal, R. Akita

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

291

285 Degradation of the epidermal growth factor receptor occurs upon cetuximab treatment

J. Doody, Y. Wang, S. Patel, R. Apblett, H. Chiang, L. Witte, P. Bohlen, D. Hicklin, P. Kussie, Y. Hadari

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

292

286 Generation of a recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) with an antitumor activity in a variety of human cancer xenograft models

I. Goetsch, A. Gonzalez, A. Beck, J.F. Haeuw, N. Corvaia

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 288 KB

english, 2004

293

287 A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and capecitabine (C) in patients with advanced solid tumors

J.W. Valle, C. Montagut, L.C. Pronk, E.T. Jones, M. Tosca, J. Beech, B. Taylor, G. Zugmaier, P. Gascon, J. Albanell

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

294

288 A trivalent bispecific fusion protein produced in myeloma cells for improved pretargeting and therapy of CEA-expressing cancers

E. Rossi, M.J. Losman, T.M. Cardillo, R.M. Sharkey, H. Karacay, W. McBride, I.D. Horak, D.M. Goldenberg, C.-H. Chang

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

295

289 Peptide-targeted alpha-radiation for melanoma therapy

Y. Miao, M. Hylarides, T. Shelton, H. Moore, D.W. Wester, D.R. Fisher, A. Fritzberg, R. Testa, T.J. Hoffman, T.P. Quinn

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

296

290 Pharmacokinetics and tissue biodistribution of a doxorubicin-antibody conjugate in mice

P. Sapra, G. Griffiths, S. Govindan, C. Damoci, J. Pickett, A. Sheerin, T. Cardillo, H. Hansen, I. Horak, D. Goldenberg

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

297

291 Preclinical evaluation of 177Lu-AMBA, a radiolabelled peptide for systemic radiotherapy and imaging of prostate cancer by targeting gastrin releasing peptide receptors

A.D. Nunn, L.E. Lantry, R. Thomas, M.E. Maddalena, J.S. Fox, T. Arunachalam, W. Feng, R.E. Swenson, M.F. Tweedle

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

298

292 A preclinical pharmacokinetic/pharmacodynamic study for anti-PDGF receptor alpha antibody 3G3 in a human glioblastoma xenograft model

N. Loizos, Y. Xu, E. Corcoran, C. Joynes, N. Covino, P. Balderas, P. Steiner, J. Tonra, D. Hicklin, P. Kussie

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

299

293 Identification of a novel prostate tumor target, RG-1, for antibody based therapy of prostate cancer

R. Parry, D. Schneider, D. Hudson, D. Parkes, J. Xuan, R. Harkins, R. Lin, B. Alicke, H. Dinter, G. Parry

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 275 KB

english, 2004

300

294 1D09C3, a human, HLA-DR-specific monoclonal antibody efficiently induces programmed cell death in lymphoid tumors

J.-B. Holz, Z. Nagy, B. Rattel, K. Lobenwein, S. Leyer, A. Krenn, S. Messemer, F. Schwaiger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 132 KB

english, 2004

301

295 Enhancing radioimmunotherapy with the PDGFr-beta inhibitor: imaging and tumor response studies

J. Baranowska-Kortylewicz, M. Abe, T. Kurizaki, K. Pietras, Z.P. Kortylewicz, J. Nearman, R.L. Mosley, C.A. Enke, A. Östman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 132 KB

english, 2004

302

296 Trastuzumab monoclonal antibody labeled with alpha-particle emitter astatine: targeted radiotherapeutic experiments on a HER2-positive breast carcinomatous meningitis animal model after intrathecal administration

A. Boskovitz, H. Ochiai, T. Okamura, X.-G. Zhao, D. Bigner, M. Zalutsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 263 KB

english, 2004

303

297 RAV12: a glycotope-specific chimeric antibody that exhibits potent cytotoxic activity against gastrointestinal tumor cell lines in vitro and in vivo

N.K. Pryer, D. Loo, P. Young, R. Winter, K. King, K. Kang, S. Coberly, T. Liang, G. Vehar, J.P. Mather

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

304

298 Development of anti-EGFR immunoliposomes for specific delivery and enhanced efficacy in EGFR-overexpressing tumors

C. Mamot, C. Rochlitz, R. Herrmann, W. Küng, R. Ritschard, J. Reuter, D.C. Drummond, K. Hong, D.B. Kirpotin, J.W. Park

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

305

299 Preclinical in vivo evaluation of a doxorubicin-antibody conjugate for treating multiple myeloma

G.L. Griffiths, P. Sapra, J. Pickett, T. Cardillo, R. Stein, S.V. Govindan, A. Sheerin, C. Damoci, I.D. Horak, D.M. Goldenberg

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 274 KB

english, 2004

306

300 Cetuximab/irinotecan/HD-FU/LV in first line therapy of metastatic colorectal cancer (CRC)

G. Folprecht, M. Lutz, P. Schoeffski, T. Seufferlein, G. Beutel, A. Nolting, M. Mueser, P. Pollert, U. Pabst, C.-H. Koehne

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

307

301 Genomic discovery, characterization and validation of a transmembrane protein overexpressed in human ovarian and pancreatic cancers: a promising new target for therapeutic monoclonal antibodies

J. Papkoff, W. Liu, T. Tang, A. Munteanu, S. Zhuo, Y. Liu, S. Salceda, R. Macina, G. Pilkington, L. Corral

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

308

302 Patterns of gene expression can prospectively predict Panitumumab (ABX-EGF) monotherapy responsiveness in xenograft models

D. Freeman, M. Boedigheimer, D. Fitzpatrick, P. Kiaei, M. Damore, C. Starnes, T. Bush, A. Coxon, J. Leal, R. Radinsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 282 KB

english, 2004

309

303 Peptide vectors for the intracellular delivery of 125I-anti-carcinoembryonic antigen (CEA) antibodies as the first step towards auger electron radioimmunotherapy

V. Garambois, M. Carcenac, M. Lehugeur, M. Pelegrin, D. Azria, P.O. Kotzki, M. Michel, A. Pelegrin

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

310

304 Pharmacokinetics of CNTO 95, a fully human MAB to human integrin receptors following single or multiple IV injections to cynomolgus monkeys

Q. Jiao, A. Fasanmade, U. Prabhakar, J. Ford, J. Cornacoff, H. Davis, M. Graham

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

311

305 In vitro evaluation of a doxorubicin-antibody conjugate, on non-Hodgkin's lymphoma and multiple myeloma cell lines

P. Sapra, G. Griffiths, M. Hayes, R. Stein, J. Pickett, S. Govindan, A. Sheerin, H. Hansen, I. Horak, D. Goldenberg

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

312

306 Construction and characterization of a novel immunotoxin consisting of two ranpirnase (rpRNAse) molecules fused to an anti-CD74 humanized IgG4 antibody

S. Vanama, C. Chang, P. Sapra, I. Horak, H. Hansen, D. Goldenberg

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 285 KB

english, 2004

313

307 Therapeutic implications of an antibody to the human macrophage-stimulating protein receptor tyrosine kinase (RON)

D. Pereira, J. O'Toole, K. Rabenau, D. Lu, V. Mangalampalli, P. Balderes, R. Bassi, D. Hicklin, D. Ludwig, L. Witte

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

314

308 Inhibition of FLT3-expressing leukemia cells by a monoclonal antibody-auristatin conjugate

Y. Li, H. Li, R. Bassi, D. Ludwig, L. Witte, D. Meyer, A. Larkin, Z. Zhu, P. Senter, D. Hicklin

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

315

309 Therapeutic efficacy of the Y-90 labeled antibody 19G9, targeting a novel protein RG-1, expressed in metastatic prostate cancer

R. Parry, D. Schneider, S. Biroc, M. Halks-Miller, H. Klocker, Y. Zhu, B. Larsen, J.S. Lewis, H. Dinter, G. Parry

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

316

310 Enhanced apoptosis and tumor regression induced by a direct agonist antibody to TRAIL-R2

S. Kataoka, K. Motoki, E. Mori, A. Matsumoto, M. Thomas, T. Tomura, R. Humphreys, V. Albert, C.F. Ware, I. Ishida

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 315 KB

english, 2004

317

311 Anti-cancer efficacy of a functional monoclonal antibody targeting melanoma-associated chondroitin sulfate proteoglycan

A. Ferry, D. Sayegh, L. da Cruz, J. de Sousa Hitzler, V. Saldivia, D. Young

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 171 KB

english, 2004

318

312 Pilot study of the use of infliximab for fatigue in advanced cancer

P. Lodge, A. Tookman, L. Jones

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 171 KB

english, 2004

319

313 Mono- and combination-therapeutic activity of panitumumab (ABX-EGF) on human A431 epidermoid and HT-29 colon carcinoma xenografts: correlation with pharmacodynamic parameters

D. Freeman, K. McDorman, T. Bush, C. Starnes, D. Cerretti, X. Yang, L. Leal, R. Radinsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 316 KB

english, 2004

320

314 Anti-tumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC-11F8) in human colon carcinoma xenograft models with enhanced activity in combination with CPT-11

M. Prewett, J.R. Tonra, R. Bassi, A.T. Hooper, G. Makhoul, B. Finnerty, L. Witte, P. Bohlen, Z. Zhu, D.J. Hicklin

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

321

315 Molecular signature of the PTEN tumor suppressor-identification of IGFBP2 as a surrogate marker for PTEN/Akt signaling

C. Chen, S. Tao, R. Shai, P. Mischel, L. Liau, J. Pinta, S. Horvath, S. Nelson, C. Sawyers

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

322

316 Cetuximab-induced clearance of the epidermal growth factor receptor (EGFR) overcomes resistance of cancer cells to EGFR tyrosine kinase (TK) inhibitors

A. Jimeno, D. Oppenheimer, M.L. Amador, A. Maitra, M. Hidalgo

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

323

317 SH3-Grb2 inhibitors inactivate HER2 signaling and enhance the anti-tumor effects of Docetaxel

B. Gril, F. Assayag, M.F. Poupon, M. Vidal, W.-Q. Liu, C. Garbay

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 288 KB

english, 2004

324

318 Dihydropyrrolopyrazoles as TGF-beta receptor kinase inhibitors for cancer therapy

J.M. Yingling, L. Yan, R.B. Peery, S.B. Peng, J. Ott, E. Dierks, X. Lin, L. Gelbert, W. McMillen, J.S. Sawyer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

325

319 Factors that govern the cell death response induced by inhibition of the molecular chaperone heat shock protein 90

M. Sherriff, P.A. Clarke, P. Workman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

326

320 Identification of potent, selective, soluble and permeable small molecule PI3 kinase inhibitors for the treatment of cancer

K. Ahmadi, W. Alderton, I. Chuckowree, P. Depledge, A. Folkes, G. Pergl-Wilson, N. Saghir, S. Shuttleworth, N. Wan, F. Raynaud, N.S.S. Saghir, N.C. Wan, A. Zhyvoloup

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 283 KB

english, 2004

327

322 Novel isoquinoline-5-sulfonamides as biochemical and cellular inhibitors of PKB/AKt

M.D. Garrett, L.J. Hunter, T. Faria Da Fonseca, J. Caldwell, M.G. Rowlands, A. Hardcastle, I. Collins, E. McDonald, N. Thompson, P. Workman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

328

323 Targeted use of combination of erbB targeted therapy

S. Bacus, N. Spector, R. Seger, Y. Yarden

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

329

324 High field MRI characterization of tumor growth kinetics, vascularity and cellularity in a PDGF-driven tv-a mouse model of glioma

J.B. Moody, P. McConville, A. Kreger, R.J. Lister, E. Trachet, W.L. Elliot, B.D. Ross, A. Rehemtulla, E.C. Holland, W.R. Leopold

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

330

325 17(allylamino)-17-demethoxygeldanamycin(17-AAG) suppresses tamoxifen-resistant breast cancer cell growth in vitro

T. Madden, D. Barrow, C.M. Dutkowski, R.A. McClelland, J.M.W. Gee, R.I. Nicholson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

331

326 Therapeutic targeting of AKT/ILK signaling in AML

M. Konopleva, Z. Zeng, Y. Tabe, Z. Estrov, Y. Lu, T.S. Daynard, G.B. Mills, M. Andreeff

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

332

327 Schedule-dependent inhibition of HIF-1alpha protein accumulation, angiogenesis and tumor growth by topotecan in U251 glioblastoma xenografts

A. Rapisarda, B. Uranchimeg, M. Hollingshead, J. Zalek, C.A. Bonomi, S.D. Borgel, J. Carter, R. Shoemaker, G. Melillo

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

333

328 Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumors)

M. Heinrich, G.A. McArthur, H. Joensuu, G.D. Demetri, S. Dimitirjevic, C.L. Corless, S. Dirnhofer, Z. Nikolova, J.A. Fletcher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 154 KB

english, 2004

334

329 Antitumor activity in preclinical xenograft models of OSI-930, a novel selective tyrosine kinase inhibitor

S.L. Winski, M.A. Bittner, P. Briner, E.N. Brown, A.R. Cooke, A. Crew, C. Hidden, C. Pirrit, M.S. Srebernak, D.L. Emerson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 154 KB

english, 2004

335

330 Magnetic resonance spectroscopy confirms the mechanism of action of the choline kinase inhibitor MN58b in human breast cancer cells

N. Al-saffar, L.E. Jackson, A. Ramirez de Molina, P. Workman, J.R. Griffiths, I.R. Judson, J.C. Lacal, M.O. Leach

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 154 KB

english, 2004

336

331 Key roles for HSP90 in tumour neoangiogenesis

S. Eccles, S. Brader, W. Court, G. Box, M. Valenti, S. Gowan, L. Patterson, Z. Ahmad, A. de Haven Brandon, P. Workman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 301 KB

english, 2004

337

332 Fragment-based and structure based optimisation of potent PKB/AKT inhibitors

P. Wyatt, D. Barford, T. Davies, S. Woodhead, G. Saxty, D. Davis, M. Garrett, F. Raynaud, S. Eccles, V. Berdini

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

338

333 Akt pathway siRNA screening using automated fluorescence imaging

R.A. Blake, P. Le, K. Ward, L. Friedman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

339

334 First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral cp-724, 714, a selective, small molecule inhibitor of her2 in patients with advanced cancer

P.N. Munster, A.W. Tolcher, C.D. Britten, K. Gelmon, S. Moulder, S. Minton, M. Mita, D. Noe, K.J. Pierce, S.P. Letrent

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

340

335 SHP-1 protein tyrosine phosphatase as a target molecule in anti-tumor immune therapies: SHP-1 inhibitor SSG interacts withIL-2 to increase anti-murine renal tumor immunity

K. Fan, M. Pathak, M. Zhou, D. Lindner, E. Borden, T. Yi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 297 KB

english, 2004

341

336 De novo resistance to epidermal growth factor receptor blockade by gefitinib in colorectal cancer cells involves increased insulin receptor isoform A signalling

H.E. Jones, J.M.W. Gee, D. Barrow, A. Wakeling, S. Guy, R.I. Nicholson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 152 KB

english, 2004

342

337 Velcade, an NF-kb inhibitor, enhances tamoxifen sensitivity in Akt-induced resistant breast cancer xenograft tumors

L. deGraffenried, W. Friedrichs, B. Chandrasekar, G. Weiss

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 152 KB

english, 2004

343

338 Computer-aided immunohistochemical analysis of EGFR signaling in paired colorectal cancer and normal colon tissue samples

W. Messersmith, D. Oppenheimer, M. Amador, J. Paralba, E. Embuscado, M. Hidalgo, C. Iacobuzio-Donahue

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 295 KB

english, 2004

344

339 Development of HDAC Class I and II specific assays in order to identify novel small molecule inhibitors

L.S. Collins, N. Khan, A. Finn, L.H. Jensen, F. McLaughlin, P.W. Finn, P. Buhl Jensen, M. Sehested

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

345

340 Effectiveness of a novel, selective inhibitor of the IGF-IR kinase against musculoskeletal tumors

K. Scotlandi, M.C. Manara, M. Serra, S. Croci, G. Nicoletti, C. Garcia-Echeverria, F. Hofmann, P. Picci

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

346

341 MEK1 inhibition enhances arsenic trioxide (ato) induced apoptosis in acute leukemia

P. Lunghi, F. Lo Coco, L. Salvatore, N. Noguera, A. Tabilio, P. Pelicci, A. Bonati

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

347

342 Anti-tumor activity, pharmacokinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model

J.D. Winkler, P.A. Lee, E. Wallace, G. Poch, K. Litwiler, T. Pheneger, J. Lyssikatos, M. Perrier, S.G. Eckhardt, T.C. Yeh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 281 KB

english, 2004

348

343 Novel role of fumarate in antagonizing VHL function

J. Isaacs, Y.J. Jung, S. Lee, C. Torres-Cabala, M. Merino, J. Trepel, B. Zbar, J. Toro, M. Linehan, L. Neckers

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

349

344 JANEX-1, a novel anti-cancer agent with anti-thrombotic properties

F. Uckun, H. Tibbles, A. Vassilev, B. Waurzyniak, X. Liu

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

350

345 The HIV protease inhibitor Amprenavir as a radiation sensitizers

A.K. Gupta, G.J. Cerniglia, R.J. Muschel, W.G. McKenna

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

351

346 Pharmacodynamic markers for the choline kinase inhibitor MN58b in human breast cancer model by magnetic resonance spectroscopy

Y. Chung, H. Troy, A. Ramirez de Molina, I.R. Judson, P. Workman, M.O. Leach, J.C. Lacal, J.R. Griffiths

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

352

347 Biological evaluation of a novel, synthetic pyrazole class of Hsp90 inhibitors

S. Sharp, K. Boxall, T. Matthews, J. Cheung, K. James, T. McDonald, M. Drysdale, P. Workman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

353

348 HER2 imaging as a non-invasive pharmacodynamic marker of Hsp90 inhibition

D.B. Solit, P.M. Smith-Jones, H. Scher, S.M. Larson, N. Rosen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

354

349 Restoration of PTEN-expression in tumor cells causes them to depend on EGFR for suppression

Q.-B. She, D. Solit, Q. Ye, K. O'Reilly, M. Moasser, N. Rosen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 288 KB

english, 2004

355

350 Clinical and molecular features of neuroblastoma tumors that can be targeted through c-Kit

S. Uccini, H.P. McDowell, O. Mannarino, U. Pauser, P.G. Natali, A. Clerico, A. Donfrancesco, P.D. Losty, R. Vitali, C. Dominici

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

356

351 C-fos mRNA levels predict response to Iressa therapy

P. Kulesza, A. Jimeno, E. Kincaid, M. Hidalgo, D. Clark

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

357

352 Constitutive activation of Akt/protein kinase B in gastric cancer: its correlation with lower invasiveness and better prognosis

J. Jung, S.Y. Nam, H.S. Lee, W.H. Kim, B.L. Lee

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

358

353 MEK blockade converts AML differentiating response to retinoic acid (RA) into extensive apoptosis: involvement of Bcl-2 modulation and ROS accumulation

M. Milella, M. Konopleva, Y. Tabe, C. Precuparu, C. Gregorj, M.R. Ricciardi, M.T. Petrucci, F. Cognetti, A. Tafuri, M. Andreeff

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

359

354 Farnesyl transferase inhibition in circulating peripheral blood mononuclear cells with the novel oral prenyl transferase inhibitor AZD3409 following single and multiple doses in volunteer studies

D. Wilson, T. Stephens, M. Bate, F. Le Maulf, P. McCormack, A. Hughes

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

360

355 Inhibition of human small cell lung cancer growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling

A. Arcaro, U.K. Khanzada, M.J. Seckl

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

361

356 Rationale for therapeutically inhibiting NFkB activity in hormone-dependent breast cancers

Y. Zhou, S. Eppenberger-Castori, G. Scott, C. Marx, U. Eppenberger, C. Benz

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 290 KB

english, 2004

362

357 IGF-I receptor kinase inhibitor NVP-AEW541-NX-7 abolishes MCF-7 breast cancer cell responsivity to estradiol

Y. Zhao, F. Hofmann, M. Pollak

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

363

358 Inhibitors of the Ras/Raf/MAPK signaling pathway sensitize pancreatic cancer cells resistant to EGFR inhibitors

V. Grünwald, M. Morgan, A. Ganser, C. Reuter

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

364

359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors

M. Campone, V. Levy, V. Delecroix, E. Bourbouloux, D. Bootle, C. Tanaka, N. Shand, F. Calvo, E. Raymond

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

365

360 NFkB expression and disease outcome in prostate cancer

J. Ross, B. Kallakury, C. Sheehan, T. Jennings

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

366

361 Preclinical activity of AZD0530, a novel, oral, potent and selective inhibitor of the Src family kinases

T.P. Green, M. Fennell, R. Whittaker, J. Curwen, V. Jacobs, J. Allen, P.A. Ple, L.F. Hennequin, G. Costello

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

367

362 Binding of gefitinib (ZD1839) to human plasma proteins: in vitro and clinical pharmacokinetic (PK) studies

J. Li, J. Brahmer, W. Messersmith, M. Hidalgo, S.D. Baker

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

368

363 Targeting of PDGF receptors; combination effects in various solid tumors and identification of a PDGF dependent brain tumor subset

A. Östman, D. Hägerstrand, K. Pietras, M. Furuhashi, Y. Wu, D.J. Hicklin, E. Buchdunger, M. Abe, M. Nister, J. Baranowska-Kortylewicz, C.-H. Heldin

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

369

364 The SRC-kinase inhibitor AZD0530 efficiently counteracts the transformation potential of BCR/ABL by targeting its kinase activity

P. Mambou, A. Romanski, G. Bug, T. Beissert, M. Kampfmann, D. Hoelzer, O.G. Ottmann, M. Ruthardt

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

370

365 Identification of a novel TGF-beta-induced signaling cascade involved in EMT and invasion of breast cancer cells

A. Viloria-Petit, B. Ozdamar, R. Bose, H.-R. Wang, M. Barrios-Rodiles, Y. Zhang, J. Wrana

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

371

366 Evaluation of Gefitinib biological effects in patients with solid tumors amenable to sequential biopsies

J. Brahmer, S. Baker, A. Spitz, J. Li, M. Rudek, W. Messersmith, A. Wolff, D. Laheru, R. Donehower, M. Hidalgo

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

372

367 Emerging pharmacokinetic (PK)-pharmacodynamic (PD) profile of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases

J. Baselga, F. Rojo, A. van Oosterom, H. Dumez, J. Huang, E. Walk, A. Mita, E. Rowinsky, C. Takimoto

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 284 KB

english, 2004

373

368 Demonstration of broad in vivo anti-tumor activity of ARRY-142886 (AZD-6244), a potent and selective MEK inhibitor

P.A. Lee, E. Wallace, T.C. Yeh, G. Poch, D. Hunt, T. Pheneger, R. Woessner, S. Cartlidge, T. Klinowska, J.D. Winkler

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

374

369 A phase II, pharmacokinetic (PK) and biological correlative study of OSI-774 (Tarceva) in patients with advanced renal cell carcinoma, with FDG-PET imaging: evidence of durable stable disease and antitumor activity

M. Beeram, E.K. Rowinsky, G.R. Weiss, A. Patnaik, A. Mita, S. Syed, M. Mita, P. O'Rourke, J.S. De Bono, A.W. Tolcher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

375

370 Cellular uptake of fluoro-2-deoxythymidine (FLT), a novel PET tracer, correlates with induction of apoptosis by erlotinib in A431 cells

J.N. Sarkaria, A.C. Mladek, C.M. Cole, R.G. Vile, C.D. James

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 283 KB

english, 2004

376

371 Signaling mediators of bystander response are potential therapeutic targets for attenuating tumor relapse

M. Natarajan, S. Mohan, C. Thomas, R. Otto, T. Herman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

377

372 A phase I/II trial of erlotinib and bexarotene in aerodigestive tract cancers

K.H. Dragnev, W.J. Petty, T.H. Davis, I. Williams, J.R. Rigas, E. Dmitrovsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

378

373 p38/JTV-1 is a novel modulator of TGF-beta required for the downregulation of c-myc and lung cell differentiation: its functional association with lung cancer formation

B. Park, M. Kim, J. Park, Y. Choi, S. Lee, J. Han, S. Kim

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

379

374 Inhibition of PI3K/AKT pathway by rhabdastrellic acid-A induced caspase-3-dependent apoptosis in leukemia cells

X. Zhu, J. Zhou, B. Xie, G. Feng, Z. Liu, D. Xiao, Y. Zeng, X. Zhang

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 281 KB

english, 2004

380

375 HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer cells in conjunction with blockade of androgen receptor, STAT3, and AKT signaling

T. Ikezoe, Y. Yang, K. Bandobashi, H.P. Koeffler, H. Taguchi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

381

376 Tolerability results with the novel oral prenyl transferase inhibitor AZD3409 following single and multiple doses in volunteer studies

D. Smethurst, D. Sandall, A. Holt, A. Lindsay, D. Wilson, A. Hughes

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

382

377 Tolerability and limited activity of perifosine in patients with advanced soft tissue sarcoma (STS): a multi-center phase 2 consortium (P2C) study

H. Bailey, M. Mahoney, S. Okuno, D. Ettinger, W. Maples, P. Fracasso, C. Erlichman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

383

378 In vivo and in vitro enhanced antitumor activity of Oxaliplatin in combination with cetuximab (C225), a chimeric monoclonal antibody anti-epidermal growth factor receptor on a panel of human colorectal tumor xenografts

D. Balin, J.P. Delord, P. Rochaix, V. Mallard, F. Thomas, I. Hennebelle, R. Bugat, P. Canal, C.B. Allal

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 279 KB

english, 2004

384

379 Characterisation of a novel class I isoform selective phosphatidyl-inositol 3-kinase inhibitor in glioma

S. Guillard, P.A. Clarke, R. te Poele, F. Di Stefano, F. Raynaud, P. Workman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

385

380 Analysis of complex PKB/Akt signaling pathways in human prostate cancer samples

V. Jendrossek, M. Henkel, J. Hennenlotter, U. Vogel, I. Mueller, M. Kuczyk, A. Stenzl, C. Belka

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

386

381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors

A. Awada, A. Hendlisz, T. Gil, B. Schwartz, S. Bartholomeus, E. Brendel, D. de Valeriola, C. Haase, T. Delaunoit, M. Piccart

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

387

382 Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study

S.C. Pacey, M.J. Ratain, P.O. O'Dwyer, H. Xiong, A. Patnaik, T. Eisen, D. Eaton, R.J. Lee, B. Schwartz, I. Judson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 291 KB

english, 2004

388

383 Preclinical antitumor activity of second generation analogs of SDX-101

S. Kanekal, B. Crain, G. Elliott, Q. Chao, J. Reifert, B. Bailey, H. Bendall, C. Niemeyer, L.M. Leoni

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

389

384 Sulindac sulfide modulates beta-catenin dependent expression of the metastasis-associated gene S100A4/mts1

U.S. Stein, W. Walther, F. Arlt, C. Fleuter, P.M. Schlag, R.H. Shoemaker

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

390

385 A phase II trial to assess the efficacy and safety of gefitinib (Iressa™) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen

G. Curigliano, O. De Cobelli, M.T. Sandri, L. Zorzino, C. Noberasco, T. De Pas, E. Scardino, V. Formica, S. Manzoni, F. de Braud

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 292 KB

english, 2004

391

386 Effect of angio-sonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumor (GIST): a preliminary report

U. De Giorgi, C. Aliberti, G. Benea, M. Conti, M. Marangolo

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

392

387 A phase I study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases

H. Dumez, P. Clement, C.H. Takimoto, A.T. van Oosterom, A. Mita, K. Parker, E.K. Rowinsky, R. Salazar, E. Martinelli, J. Baselga

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

393

388 The abrogation of rapamycin-induced AKT activity by the small molecule IGF-IR inhibitor, AEW541, and the enhanced antitumor activity of combined mTOR and IGF-IR inhibition

K. O'Reilly, Q. She, H. Lane, F. Hofmann, D. Solit, N. Rosen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

394

389 CF101, an agonist to the A3 adenosine receptor enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model

P. Fishman, S. Bar Yehuda, L. Madi, D. Silberman, G. Slosman, M. Shkapenuk

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 285 KB

english, 2004

395

390 A phase I trial of weekly AP23573, a novel mTOR inhibitor, in patients with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis

A.A. Desai, L. Janisch, L. Berk, H.L. Knowles, V.M. Rivera, H.L. Kindler, W.M. Stadler, C.L. Bedrosian, M.J. Ratain

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

396

391 Proof of principle trial uncovers cyclin D1 as a marker of response to erlotinib

W.J. Petty, K.H. Dragnev, V.A. Memoli, T.H. Davis, L.D. Lewis, W.C. Nugent, J.R. Rigas, E. Dmitrovsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

397

392 Targeting janus kinase 3 with JANEX-1 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice

M. Cetkovic-Cvrlje, B. Waurzyniak, X.P. Liu, F. Uckun

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 262 KB

english, 2004

398

393 A phase II study of OSI-774 given in combination with carboplatin in patients with recurrent ovarian cancer (NCIC IND.149)

H. Hirte, K. Swenerton, A. Oza, S. Ellard, M. Plante, R. Grimshaw, M. Carey, L. Seymour, B. Fisher, W. Walsh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 123 KB

english, 2004

399

394 Inhibition of Kit-dependent tumor growth by OSI-930, a novel selective tyrosine kinase inhibitor

A.J. Garton, L. Castaldo, J. Kahler, M. O'Connor, S. Nitzan, S. Winski, M. Srebernak, J. Keily, A.-H. Li, G. Wynne

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 123 KB

english, 2004

400

395 Blocking the interaction between HIF-1alpha and p300 by a 32 amino acid fragment of p35srj inhibits the hypoxia induced transcriptional activity of HIF-1alpha in human U87MG glioma cells

S. Latini, K.S. Jensen, L.S. Olsen, J. Finneman, M.W. Madsen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 123 KB

english, 2004

401

396 Sphingosine 1-phosphate (S1P) differently modulates migration of gastric cancer cell

H. Yamashita, J. Kitayama, D. Shida, H. Yamaguchi, K. Mori, Y. Takuwa, H. Nagawa

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

402

397 Aurocrine interleukin-8 signalling in prostate cancer cells promotes translation of cyclin D1

C.F. MacManus, M. Hamill, J. Pettigrew, P.G. Johnston, D.J.J. Waugh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

403

398 Development of an LC/MS/MS method for the quantitative determination of the Akt inhibitor PIA5 in mouse plasma

N.F. Smith, A. Sparreboom, P.A. Dennis, W.D. Figg

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

404

399 Constitutive erbB family phosphorylation in osteosarcoma as a target for CI 1033 inhibition

D. Thomas, D. Hughes, T. Giordano, K. McDonagh, L. Baker

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

405

400 Gefitinib in liver cancer: could laminin-5 expression be a good predictive factor?

A. Paradiso, A. Azzariti, L. Porcelli, G.M. Simone, E. Fransvea, S. Antonaci, G. Giannelli

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

406

401 TGFb is a major factor constitutively acting on T cells in vivo: implications for cancer immunotherapy

T. Zander, D. Re, S. Beyer, R.K. Thomas, M. Hellmich, A. Popov, J. Wolf, S. Debey, J.L. Schultze

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

407

402 Differential expression of biomarkers in NSCLC: a comparison between smokers and never smokers

T. Dutu, M. Erman, F. Penault-Llorca, P. Validire, D. Grunenwald, L. Morat, L. Sabatier, T. Le Chevalier, J. Armand, J. Soria

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

408

403 Regulation of matrix metalloproteinase 3 by tumor-associated mutant E-cadherin variants

M. Fuchs, C. Hermannstädter, K. Specht, P. Knyazev, A. Ullrich, E. Rosivatz, P. Hutzler, R. Busch, H. Höfler, B. Luber

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

409

404 Clinical significance of insulin-like growth factor-binding protein-3 expression in advanced gastric cancer

J.O. Park, C.K. Park, S.H. Lee, K. Kim, W.S. Kim, C.W. Jung, Y.S. Park, Y.H. Im, W.K. Kang, K. Park

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

410

405 Potent antiproliferative effects of Src kinase inhibition in a model of neuropeptide-induced androgen-independent prostate cancer

J.C. Yang, J.E. Busby, H.-J. Kung, C.P. Evans

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

411

406 Reduction of in vitro metastatic potential of tamoxifen-resistant breast cancer cells following inhibition of Src kinase activity by AZD0530

S. Hiscox, L. Morgan, T. Green, R. Nicholson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 295 KB

english, 2004

412

407 Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression correlates with responsiveness of human tumor xenografts to receptor tyrosine kinase inhibition

R.A. Bras-Goncalves, J.G. Judde, M.-F. Poupon

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

413

408 A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL-002e/NCIC CTG IND.157)

E. Winquist, D. Soulieres, E. Chen, M. Tsao, M. Klein, G. Pond, J. Dancey, E. Eisenhauer, L.L. Siu

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

414

409 AP23573, an mTOR inhibitor, administered IV daily × 5 every other week in patients with refractory or advanced malignancies — a phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study

M. Mita, E. Rowinsky, A. Mita, S. Syed, Q. Chu, M. Goldston, H. Knowles, V. Rivera, C. Bedrosian, A. Tolcher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

415

410 Insulin stimulation of head/neck squamous cancer cells confers resistance to the anti-proliferative effects of an EGFR kinase inhibitor

C. Thomas, M. Jamison, A. Beckler

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

416

411 Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase 1 clinical trials

V. Rivera, L. Berk, M. Mita, A. Tolcher, E. Rowinsky, A.A. Desai, M.J. Ratain, T. Clackson, C.L. Bedrosian

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

417

412 A phase I and pharmacokinetic study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases

A. Mita, C.H. Takimoto, E. Martinelli, H. Dumez, C. DiLea, W. Mietlowski, J. Tabernero, M. Dugan, N. Isambert, A.T. van Oosterom

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

418

413 Pharmacokinetic/pharmacodynamic analysis of OSI-930, a novel selective tyrosine kinase inhibitor with anti-tumor activity

A. Garton, J. Kahler, L. Castaldo, Y. Yao, A. Franks, D. Henninger, M. Srebernak, A. Cooke, M. Bittner, A. Crew

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 289 KB

english, 2004

419

414 Correlation of mutations in EGFR with clinical outcomes in NSCLC patients treated with erlotinib

D. Eberhard, L. Amler, A. Goddard, W. Ince, T. Januario, K. Hillan, M. Ostland, D. Ramies, S. Seshagiri, P. Klein

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

420

414A Pharmacological properties and in vitro and in vivo antitumour activity of the potent and selective PI3 kinase inhibitor PI103

P. Workman, F. Raynaud, P. Clarke, R. Te Poele, S. Eccles, L. Kelland, F. Di Stefano, K. Ahmadi, P. Parker, M. Waterfield

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

421

415 Discovery and evaluation of inhibitors of cyclin E2-CDK2 and cyclin B1-CDK1

S. Coats, M. Payton, G. Chung, P. Yakowec, D. Powers, N. Zhang, J. Leal, A. Tasker, B. Askew

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

422

416 Simultaneous targeting of tumor cell proliferation and tumor-induced neoangiogenesis by the novel CDK2/VEGF-RTK dual pathway inhibitor ZK-CDK

G. Siemeister, H. Briem, T. Brumby, M. Haberey, R. Jautelat, M. Krüger, U. Lücking, A. Reichel, M. Schäfer, K. Bosslet

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

423

417 The ATM-Chk2 kinase pathway: molecular interaction maps and therapeutic rationale

Y. Pommier, M. Aladjem, K.W. Kohn

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

424

418 Cytoplasmic localization of p21 cip1/WAF1 is a poor prognostic marker in the breast cancer patients

W. Xia, J.-S. Chen, X. Zhou, D.-F. Lee, Y. Liao, B. Zhou, M.-C. Hung

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

425

419 Automated quantitative in-situ method of protein analysis (AQUA) demonstrates that components of the retinoblastoma (Rb) pathway are potential molecular targets in oropharyngeal squamous cell cancer

A. Psyrri, Y. Ziwei, P.M. Weinberger, B. Haffty, C. Sasaki, R.L. Camp, D.L. Rimm

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 269 KB

english, 2004

426

420 The combination of Indisulam (E7070) with cisplatin, oxaliplatin and 5-fluorouracil are synergistic in vitro and in vivo

Y. Ozawa, T. Owa, A. Yokoi, K. Yoshimatsu, M. Asada

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 126 KB

english, 2004

427

421 Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells

C. Voland, A. Bord, A. Peleraux, G. Penarier, D. Carriere, O. Jbilo, P. Casellas

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 126 KB

english, 2004

428

422 The mode of action of CYC202 (R-roscovitine) a cyclin dependent kinase inhibitor currently in phase II clinical trials

S. Green, D.E. MacCallum, I.N. Fleming, J. Melville, M. Watson, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D.P. Lane

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 126 KB

english, 2004

429

423 Cyclin-dependent kinase (CDK) inhibitor CYC202 (R-roscovitine) induces clock gene mPer2 mRNA expression rhythm in tumor: relevance for antitumor efficacy

E. Filipski, M. Filipski, H. Georgsson, A. Gianella-Borradori, F. Levi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

430

424 In vivo and in vitro anticancer activity of the lanthanum compound KP772 (FFC24)

P. Heffeter, M.A. Jakupec, M. Micksche, M. Hauses, N. Graf von Keyserlingk, B.K. Keppler, W. Berger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

431

425 The role of p27 in efficacy of chemo- and radiosensitivity of primary mouse squamous carcinoma cells

A. Grosse-Wilde

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

432

426 PTEN inactivation is a common event in childhood leukemia

S. Zheng, J. Wiencke, J. Wiemels, M. Smith, P. Buffler

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 280 KB

english, 2004

433

427 Identification of response marker genes of the antitumor sulfonamide indisulam (E7070)

T. Owa, Y. Ozawa, A. Yokoi, T. Nagasu, F.G. Renshaw, M. Yule

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

434

428 Elevated Skp2 protein expression and its association with cytoplasmic mislocalization of p27Kip1 protein in acute myelogenous leukemia: its prognostic value

J. Cheong, J. Kim, J. Lee, S. Lee, J. Hahn, Y. Ko, Y. Min

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

435

429 Cyclin D1, P27 and Skp2 expression in non-small cell lung cancers (NSCLC)

T. Jennings, C. Sheehan, J. Ross

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

436

430 Phase I and pharmacokinetic study of UCN-01 (U) in combination with irinotecan (I) in patients with solid tumors

A. Jimeno, M.A. Rudeck, W.T. Purcell, Y. Zabelina, K. Elza-Brown, T. Rogers, J.E. Dancey, S.D. Baker, M. Carducci, R. Donehower

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

437

431 Phase I and pharmacokinetic study of indisulam (E7070) in combination with carboplatin, a CESAR Central European Society for Anticancer Drug Research — EWIV report

C. Dittrich, M. Gneist, A. Zandvliet, C. Johnston, M. Yule

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

438

432 Identification of clinically relevant pharmacodynamic biomarkers in patients treated with the CDK inhibitor CYC202 (R-roscovitine)

S.R. Green, S. Frame, K. Watt, S. Anderson, I.N. Fleming, D.E. MacCallum, J. Melville, M. Watson, A. Gianella-Borradori, D.P. Lane

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

439

433 A comparison of clinicopathological features and molecular markers in British and Nigerian women with breast cancer

I.D. Gukas, B.A. Jennings, B.M. Mandong, A. Girling, G. Igun, W. Prime

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 290 KB

english, 2004

440

434 The interactions of acyclic nucleotide analogues with human telomerase

M. Hájek, N. Matulová, I. Votruba, A. Holy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

441

435 Biophysical, biological, and in silico investigation of 3,6,9-trisubstituted acridines targeting human telomeric G-quadruplex DNA

C. Schultes, M.J.B. Moore, B. Guyen, S. Neidle

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

442

436 The novel compound KML001 induces telomere attrition, senescence and chromosomal instability in cell lines with short telomeres

H.R. Hendriks, F. Dai, B. Rademaker, Y.J. Yang, S.B. Lee, A.M. Burger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 294 KB

english, 2004

443

437 Targeting telomere maintenance in childhood neuroblastoma and primitive neuroectodermal brain tumors

N. Binz, T. Shalaby, A. Eggert, M.A. Grotzer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

444

438 Mesenchymal progenitor cells as gene delivery systems for cancer and leukemia therapy

M. Andreeff, M. Studeny, J. Dembinski, M. Cabreira-Hansen, C. Zompetta, T. McQueen, J. Fueyo, R.E. Champlin, F. Lang, F.C. Marini

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

445

439 TGF-beta2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: safety and efficacy results of phase I/II clinical studies

K. Schlingensiepen, P. Hau, A. Brawanski, J. Schlaier, M. Mehdorn, G. Wurm, J. Pichler, M. Kunst, G. Stauder, U. Bogdahn

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 293 KB

english, 2004

446

440 Effects of bispecific antisense oligonucleotide targeting both insulin-like growth factor binding proteins 2 and 5 on cell survival and apoptosis in prostate cancer model

M. Signaevsky, S. Kijama, E. Beraldi, M. Cox, M. Gleave

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

447

441 Sensitizing NSCLC to chemotherapy by Bcl-2 siRNA — what is the optimal chemo combination?

D. Losert, M. Mueller, V. Wacheck

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

448

442 Depletion of DNA methyltransferase (DNMT)1, and/or DNMT3b mediates growth arrest and apoptosis in lung and esophageal cancer cells

D.S. Schrump, E. Kassis, M. Zhao, J.A. Hong, G.A. Chen, D.M. Nguyen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

449

443 Decreased expression of DNMT1 at the mRNA level following 7 day infusion of the antisense compound MG98 in a phase I study

M. Leslie, S.A. Coulthard, E.R. Plummer, I. Judson, J.S. de Bono, L. Vidal, A. Greystoke, C. Lee, A.V. Boddy, A.H. Calvert

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 295 KB

english, 2004

450

444 A phase I/II study of oblimersen sodium in combination with oxaliplatin, 5-FU and leucovorin (FOLFOX4 regimen) in patients with advanced colorectal cancer

C. Mita, M. Goldston, J. Kuhn, M.J. Egorin, M. Beeram, A. Patnaik, M.M. Mita, J.S. DeBono, E.K. Rowinsky, A.W. Tolcher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 154 KB

english, 2004

451

445 Genasense (G3139) causes apoptosis in melanoma cells by multiple mechanisms

C.A. Stein, J. Lai, L. Benimetskaya, E. Hua, S. Wu

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 154 KB

english, 2004

452

446 Evaluation of a cancer-specific Ad vector (Ad5-Id-1-luc) in the detection and monitoring of breast cancer

T. Chaudhuri, Z. Cao, P. Simhadri, H. Wu, A. Stargel, K. Zinn

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 286 KB

english, 2004

453

447 Retargeting adenoviral gene therapy vectors to bladder tumours over-expressing EGFR and other cell surface markers

D. Burdon, T.J. Harvey, P.J. Selby, J.D. Chester

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

454

448 Targeting protein kinase CK2 for induction of apoptosis as an approach to cancer therapy

K. Ahmed, J. Slaton, G. Wang, G. Unger, A. Davis

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

455

449 Treatment of pancreatic cancer by TGF-beta2 suppression mediated by the antisense oligonucleotide AP 12009: preclinical efficacy data

G. Stauder, A. Bischof, T. Egger, M. Hafner, H. Herrmuth, M. Kielmanocwicz, P. Jachimczak, R. Schlingensiepen, K. Schlingensiepen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

456

450 The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies

K. Schlingensiepen, A. Bischof, T. Egger, M. Hafner, H. Herrmuth, P. Jachimczak, M. Kielmanowicz, E. Zavadova, G. Stauder

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

457

451 Irradiation-driven tumor selectivity of liposome-based gene therapy targeting Akt activation

P. Martinive, P. Sonveaux, O. Feron

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 153 KB

english, 2004

458

452 The oncolytic reovirus, Reolysin, augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT116

S. Wadler, B. Yu, M. Lane, L. Klampfer, T. Sasazuki, S. Shirasawa, M. Coffey

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 153 KB

english, 2004

459

453 Validation of pharmacodynamic assays to determine the clinical effect of an antisense to the XIAP inhibitor of apoptosis

J. Cummings, T.H. Ward, E. LaCasse, C. Lefebvre, M. St.-Jean, M. Dawson, J. Durkin, M. Ranson, C. Dive

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 153 KB

english, 2004

460

454 Highly active, cancer specific promoters for gene therapy of small cell lung cancer

N. Pedersen, M.W. Pedersen, H.S. Poulsen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 299 KB

english, 2004

461

455 ARHI gene therapy and paclitaxel exert additive cytotoxicity for breast cancer cells through caspase-independent and caspase-dependent apoptotic mechanisms

Y. Yu, J. Bao, B. Fang, Z. Lu, R.Z. Luo, R.C.J. Bast

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

462

456 Mesothelial cells as target of antiangiogenic therapy for peritoneal metastasis

A. Sako, J. Kitayama, H. Nagawa

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

463

457 Interim evaluation of a multi-institution phase I/II study of antisense oligonucleotide GTI-2040 (G) and capecitabine (C) in patients with metastatic renal cell carcinoma (mRCC)

A.A. Desai, R. Bukowski, P. Murray, B. Poiesz, D. Quinn, M. Saltzman, J. Wright, A. Young, W.M. Stadler, F.M. Torti

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

464

458 What has 30 years of angiogenesis research and drug development taught us about cancer treatment?

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 123 KB

english, 2004

465

459 Targeting VEGF with Avastin

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 123 KB

english, 2004

466

460 Clinical development of AVE 8062 and ZD6126

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 123 KB

english, 2004

467

461 Tyrosine kinase inhibitors that target more than the VEGF-R: SU 11248 and ZD6474

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 123 KB

english, 2004

468

462 Targeting apoptosis in cancer with APO2L/TRAIL

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 123 KB

english, 2004

469

463 Translation targeting TRAIL receptors to the clinic

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 414 KB

english, 2004

470

464 Regulation of apoptosis by synthetic helices of the BCL-2 family

L. Walensky, A. Kung, I. Escher, T. Malia, S. Barbuto, R. Wright, G. Wagner, G. Verdine, S. Korsmeyer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 132 KB

english, 2004

471

465 Targeting Bcl-2 using antisense molecules

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 277 KB

english, 2004

472

466 Antibody therapies targeting the stromal compartment

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

473

467 Stromal compartment influences on response to therapy

A.F. Chambers, S.A. Vantyghem

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

474

468 Brain metastases: molecular analysis and therapeutic options

P. Steeg, J. Bronder, R. Weil, A. Stark, H. Mehdorn, S. Davis, P. Meltzer, M. Merino, D. Palmieri

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

475

469 Environmental mediated drug resistance (EMDR) in hematologic malignancies

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 132 KB

english, 2004

476

470 Efficacy of nemorubicin (MMDX) administered with iodinated oil via hepatic artery (IHA) to patients with unresectable primary hepatocellular carcinoma (HCC): phase II trial

Y. Sun, J. Yang, P. Luo, Y. Zhang, Y. Yan, L. Sun, M.A. Pacciarini, O. Valota, C. Geroni

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 275 KB

english, 2004

477

471 In vitro and in vivo antitumor activity of nemorubicin metabolites

C. Geroni, R. Battaglia, M. Floreani, D. Ballinari, A. Marsiglio, L. Quintieri

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

478

473 Poly(ADP-ribose) polymerase inhibitor, ABT-472 enhances antitumor activity of doxorubicin in human xenograft models and protects against drug-induced cardiac toxicity

I. Joseph, D. Ferguson, J. Palma, M. Refici, L. Godzicki, L. Rodriguez, D. Frost, S. Rosenberg, R. Grandel, W. Wernet

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

479

474 Expression of the DNA damage repair gene p53r2 is predictive of survival of patients with lung cancer

G. Bepler, S. Sharma, Z. Zheng

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

480

475 The caffeine derivative 1,3-dipropyl-7-methylxanthine selectively inhibits the ATM kinase and causes sensitisation to ionising radiation in vitro

C.J. Richardson, G.C.M. Smith

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

481

476 Germline MYH mutations and risk of colorectal cancer

M. Croitoru, S. Cleary, N. Di Nicola, M. Manno, M. Aaronson, M. Redston, M. Cotterchio, J. Knight, R. Gryfe, S. Gallinger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

482

477 Dss1, a homolog of the split hand/split foot malformation candidate gene, is required for cell survival following exposure to topoisomerase II targeting agents

M. Malik, J. Nitiss

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 280 KB

english, 2004

483

478 Preclinical investigation of novel inhibitors of DNA dependent protein kinase

M.A. Batey, Y. Zhao, H.D. Thomas, G.C.M. Smith, D.R. Newell, N.J. Curtin

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

484

479 Impact of the DNA repair efficiency in the outcome of sarcoma patients treated with ET-743 (Yondelis)

A. van Oosterom, R. Maki, M. Taron, R. Sciot, J.M. Fernandez Sousa-Faro, J.C. Tercero, J. Jimeno, R. Rosell

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

485

480 The ING family tumor suppressor genes enhance nucleotide excision repair

E.I. Campos, W.H. Kuo, M.Y. Chin, D.L. Mitchell, G. Li

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

486

481 Expression and prognostic significance of phosphorylated histone H2AX in chronic myelogenous leukemia

J. Cheong, H. Jeung, J. Kim, J. Lee, S. Lee, J. Hahn, Y. Ko, Y. Min

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 268 KB

english, 2004

487

482 Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells

G.P. Margison, J. Heighway, S.J. Pearson, K.L. Harrison, K. Rhode, P.V. Barber, P.N. O'Donnell, A.C. Povey, M.F. Santibáñez Koref

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 133 KB

english, 2004

488

483 Polymorphisms of DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma

A.G. Casson, S.C. Evans, Z. Zheng, P.J. Veugelers, G.A. Porter, D.L. Guernsey

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 133 KB

english, 2004

489

484 In vivo induction of resistance to gemcitabine results in amplification of ribonucleotide reductase as the major determinant

A.M. Bergman, P. Eijk, V. Ruiz van Haperen, K. Smid, G. Veerman, P. Van den Ijssel, B. Ylstra, G. Peters

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 269 KB

english, 2004

490

485 Rationale for combination of SDX-102 with Alimta in MTAP-negative tumors

L.M. Leoni, C. Niemeyer, H. Bendall, B. Bailey, J. Reifert, G. Elliott

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

491

486 A phase I study of pemetrexed supplemented with folic acid (FA) and vitamin b12 (VB12) in Japanese patients with solid tumors

K. Nakagawa, S. Kudoh, K. Matsui, S. Negoro, N. Yamamoto, J. Latz, S. Adachi, M. Fukuoka

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

492

487 Correlations of in vitro chemosensitivity of solid tumors to Pemetrexed (P, ALIMTA®) and target gene expression

O. Oberschmidt, U. Eismann, M. Ehnert, S. Struck, J. Blatter, M. Lahn, D. Ma, C. Niyikiza, P. Paoletti, A.H. Hanauske

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 279 KB

english, 2004

493

488 VX-944: an inosine monophosphate dehydrogenase inhibitor with unique anti-cancer activity

J. Jain, S. Almquist, R. Hoover, D. Shlyakhter, P. Ford, W. Markland, L. Dauffenbach, C. Kerfoot, R. Mosher

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

494

489 5,10-methylenetetrahydrofolate decreases 5-fluorouracil systemic toxicity without concomitant loss of antitumor activity

M.J. Cantwell, J.M. Robbins

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

495

490 Synergistic combination of SDX-102 with docetaxol or 5-fluorouracil in pre-clinical models of lung and pancreatic cancer

L.M. Leoni, C. Niemeyer, H. Bendall, B. Bailey, J. Reifert, B. Crain, G. Elliott, K. Kanekal

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

496

491 The prognostic significance of 18F-misonidazole (FMISO) PET-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with and without tirapazamine

D. Rischin, R. Hicks, R. Fisher, D. Binns, J. Corry, S. Porceddu, M. Grossi, C. O'Kane, L. Peters

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

497

492 Novel hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with improved extravascular transport: analogues of Tirapazamine with in vivo activity

M.P. Hay, R.F. Anderson, W.A. Denny, K.O. Hicks, F.B. Pruijn, B.G. Siim, W.R. Wilson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

498

493 Exploiting nitric oxide synthase (NOSII) overexpression in hypoxic tumour cells to improve response to the bioreductive drug AQ4N

E. Chinje, S. Singh, R. Cowen, B. Telfer, K. Williams, I. Stratford, P. Harris, C. Dunk

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

499

494 Preliminary results from a phase I clinical trial of the bioreductive drug, RH1

T.H. Ward, S. Danson, M. Dawson, O. Denneny, H. McGrath, J. Cummings, P. Johnson, C. Dive, M. Ranson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

500

495 The synthesis of novel 3- and 5-piperidinyl substituted indolequinone bioreductive prodrugs: mechanism of hypoxic/reductive activity

I. Robinson, I. Mrema, I.J. Stratford, M. Jaffar

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

501

496 Water-soluble dinitrobenzamide mustard phosphate pre-prodrugs as hypoxic cytotoxins

W.R. Wilson, S.M. Pullen, A. Degenkolbe, D.M. Ferry, N.A. Helsby, K.O. Hicks, G.J. Atwell, S. Yang, W.A. Denny, A.V. Patterson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

502

497 A bioreductive prodrug of combretstatin A4

P.D. Davis, P. Thomson, M.A. Naylor, S.A. Everett, M.R.L. Stratford, K.B. Patel, P. Wardman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 240 KB

english, 2004

503

498 Selective potentiation of the hypoxic cytotoxicity of the bioreductive drug tirapazamine

B.G. Siim, R. Patel, F.B. Pruijn, M.P. Hay, W.R. Wilson

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 108 KB

english, 2004

504

499 N(O)-(Substituted)-b-(2),4,5-tetramethyl-3,6-dioxo-1,4-cyclo-hexadinen-1-propa(noate) propanoamide: bioreductive delivery systems for selective delivery of therapeutic agents into solid tumours

R. Tanner, N. Abou-Zeid, L.T. Glassbrook, R.M. Phillips, I.J. Stratford, M. Jaffar

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 108 KB

english, 2004

505

500 Bioreductive activation and in vitro cytotoxicity of MUP03/704: a novel bioreductive cytotoxic drug conjugate for solid tumours

M. Volpato, P.M. Loadman, N. Abou Zeid, M. Jaffar, I.J. Stratford, R.M. Phillips

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 243 KB

english, 2004

506

501 Prospective UGT1A1 genotyping in a phase I study of safety and pharmacokinetics of liposome encapsulated SN-38 (LE-SN38)

P.M. LoRusso, M.N. Fishman, E.H. Kraut, M.S. Gordon, Y.A. Elsayed, J.L. Steinberg, J.A. Nieves, S.P. Wanaski, J.L. Dul, J.W. Sherman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

507

502 SUMO conjugation and proteolysis regulate cell sensitivity to DNA topoisomerase I poisons

H. Jacquiau, R. van Waardenburg, C. Lancaster, B. Schulman, M.-A. Bjornsti

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

508

503 First results of diflomotecan, a new topoisomerase 1 inhibitor, as oral soft-gel capsules in a phase I dose escalation study in patients with advanced malignant solid tumours

T. Lesimple, P. Fumoleau, A. Lortholary, J. Egreteau, M. Campone, P. Soulie, B. Le Mosquet

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 284 KB

english, 2004

509

504 Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies

C. Takimoto, S. Syed, M. McNamara, J. Doroshow, S. Pezzulli, E. Eastham, A. Bernareggi, J. Dupont

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

510

505 Human carboxylesterase isoform 2 (hCE2) mRNA expression in peripheral blood lymphocytes as a predictive marker of irinotecan activation rate in vivo

E. Cecchin, G. Corona, S. Masier, P. Biason, G. Cattarossi, S. Frustaci, A. Buonadonna, A.M. Colussi, M. Boiocchi, G. Toffoli

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 151 KB

english, 2004

511

506 Durable disease stabilization and antitumor activity with rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, in combination with gemcitabine: a phase I and pharmacokinetic study in patients with advanced cancer

E. Calvo, E.K. Rowinksy, A.W. Tolcher, Q.S. Chu, M. Beeram, A. Mita, K. Mettinger, M. Knepper, A.D. Goetz, A. Patnaik

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 284 KB

english, 2004

512

507 Role of topoisomerase I inhibition in the cytotoxic action of synthetic derivatives of the anticancer marine alkaloid lamellarin D

A. Lansiaux, W. Laine, C. Tardy, M. Iwao, F. Ishibashi, C. Bailly

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

513

508 A National Comprehensive Cancer Network phase II study of gemcitabine and irinotecan in metastatic breast cancer: can topoisomerase I localization predict response to irinotecan?

S. Moulder, N. Valkov, S. Minton, P. Munster, R. Lush, M. Lacevic, I. Sims, A. Cammarata, J. Horton, D. Sullivan

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

514

509 Antitumour activity of the novel 7-substituted camptothecin ST1481 (Gimatecan) in human neuroblastoma

A.M. Di Francesco, D. Meco, A. Riccardi, G. Barone, C. Pisano, P. Carminati, S. Rutella, M. D'Incalci, R. Riccardi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 274 KB

english, 2004

515

510 Pharmacokinetics (PK) and effects on irinotecan (CPT-11) disposition of selenium (Se) during a phase I study of CPT-11 in combination with selenomethionine (SLM) in patients with advanced solid tumors

L. Pendyala, P. Smith, M. Fakih, P. Creaven, J. Prey, M. Murphy, Y. Rustum

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

516

511 Potentiation of cell sensitivity to the DNA topoisomerase I inhibitor gimatecan by TRAIL in prostate carcinoma cells

P. Perego, E. Ciusani, N. Carenini, F. Zunino

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

517

512 BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo

D. Demarquay, M. Huchet, H. Coulomb, L. Lesueur-Ginot, O. Lavergne, J. Camara, P.G. Kaspryzk, G. Prevost, D.C.H. Bigg

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 142 KB

english, 2004

518

513 Design of the selective DNA topoisomerase I poison, NU:UB 235

D.J. Mincher, L. Young, H. Downing, A. Turnbull, G. Kay, M.C. Bibby

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 272 KB

english, 2004

519

514 Pharmacokinetic study of the distribution, metabolism and excretion of non-radiolabeled DX 8951f following repeated intravenous administration to patients with solid tumors

M. Beeram, E.K. Rowinsky, A. Patnaik, A. Mita, L. Forero, L. Wood, A.W. Tolcher, M. Kamida, R.L. De Jager, C.H. Takimoto

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

520

515 Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with potent activity toward solid tumors

K. Lemke, W. Laine, C. Bailly, A.K. Larsen, A. Skladanowski

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

521

516 Disruption of PKCzeta elicits hypersensitivity to submicromolar amounts of etoposide independently of the non-homologous end-joining pathway

C. Reis, N. Giocanti, C. Hennequin, F. Mégnin-Chanet, M. Fernet, R. Filomenko, A. Bettaieb, E. Solary, V. Favaudon

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 272 KB

english, 2004

522

517 AQ4N mediated potentiation of chemoradiotherapy in human lung tumour xenografts

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

523

518 Alterations of topoisomerase IIalpha, associated with in vivo resistance to tafluposide, are partially reversible

A. Kruczynski, L. Creancier, Y. Menon, N. Chansard, J. Astruc, S. Roy, J.-M. Barret, C. Bailly

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

524

519 Preclinical evaluation of the second generation vascular disrupting agent OXI 4503

W. Shi, H.W. Salmon, A.M. Rojiani, D.W. Siemann

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 286 KB

english, 2004

525

520 Modulation of N,N-dimethylamino-benzoylphenylurea (BPU) absorption by the CYP3A and ABCG2 inhibitor ritonavir

M.A. Rudek, N.F. Smith, M. Zhao, P. He, E.R. Lepper, W.D. Figg, A.D. Colevas, S.D. Baker, A. Sparreboom

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

526

521 New synthetic Epothilone derivative ZKEPO inhibits the proliferation of a human glioma implanted orthotopically in nude mice

J. Hoffmann, R.B. Lichtner, A. Rotgeri, I. Fichtner, U. Klar

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

527

522 Oral taxane BMS-275183 demonstrates therapeutic synergy in human tumor xenografts when combined with cetuximab

W. Rose, R. Wild

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

528

523 Selective targeting of cancer cell tubulin with anti-tumor drugs

A.S. Davis, S.M. Martinez, P. Thepchatri, D.A. Nelson, J.L. Watt, J.P. Snyder, K.M. Middleton

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 282 KB

english, 2004

529

524 MST-997: a novel taxane with superior efficacy that overcomes paclitaxel and docetaxel resistance in vitro and in vivo

D. Sampath, C. Discafani, C. Beyer, H. Liu, T. Annable, S. Musto, P. Gallagher, C. Rios, F. Loganzo, L.M. Greenberger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

530

525 Functional characterisation of beta-tubulin mutations: Insights into paclitaxel/tubulin interactions

M. Kavallaris, M. Liu

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

531

526 Optimisation of a pre-clinical dosing schedule for the novel epothilone analogue ABJ879 based on tumour interstitial fluid pressure modulation in rat mammary tumour models

P.M.J. McSheehy, M. Becquet, S. Ferretti, J. Brueggen, A. Schweitzer, M. Wartmann

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 275 KB

english, 2004

532

527 ILX651 inhibits polymerization of alpha beta III tubulin and is cytotoxic to beta tubulin mutant tumor cell lines that overexpress beta III tubulin

M. Kavallaris, R. Luduena, M. Lu, V. Prasaad, L. Hammond, K. Stephenson, L. Arthaud, S. Weitman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

533

528 The orally effective taxane DJ-927 has little ability to induce drug resistance in human non-small cell lung cancer cells

Y. Ochi, M. Minami, A. Togho

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

534

529 Nonlinear pharmacokinetic modeling of XAA296 administered to patients with advanced solid tumors once every 3 weeks (q3w) intravenously (IV) in a phase I clinical trial

C. Hsu, T. Chen, A. Mita, A.C. Lockhart, M. Moricz, L. Alland, G. Taccard, E. Rowinsky, M.L. Rothenberg, S. Sharma

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

535

530 Oxi 4503: a novel combretastin analog with both single agent activity and the ability to enhance radiation response

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 279 KB

english, 2004

536

531 Signaling dependent phosphorylation of tubulin folding factor controls microtubule biogenesis and functions: a new potential target in cancer cells

R. Kumar, R.K. Vadlamudi, C.J. Barnes, S. Balasenthil

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

537

532 The seco-taxane idn5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance

C. Ferlini, S. Mozzetti, G. Raspaglio, F. Filippetti, D. Gallo, L. Cicchillitti, P. Morazzoni, C. Manzotti, E. Bombardelli, G. Scambia

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

538

533 ABT-751 enhances the efficacy of 5-FU, cisplatin and gemcitabine in preclinical xenograft models

I. Joseph, D. Ferguson, J. Palma, V. Bontcheva-Diaz, D. Frost, S. Rosenberg, H.L. Sham

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

539

534 Ixabepilone, a novel tubulin interacting agent, given every other week in combination with irinotecan in patients with advanced malignancies: a phase i and pharmacokinetic study

S. Faivre, C. Delbaldo, P. Pautier, V. Boige, S. Henriet, F. Namouni, C. Eyndels, R. Peck, J. Armand, E. Raymond

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 136 KB

english, 2004

540

535 Phase I study of a new Halichondrin B analog, E7389, administered by 1-hour IV infusion every 21 days

Y.A. Elsayed, L. Rosen, V. Rajeev, L. Wiggins, E. Liang, C. DesJardins, S. Woeppel, A. Kornowski

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 136 KB

english, 2004

541

536 A phase 1 study of Epothilone B analog BMS-247550 in combination with carboplatin in recurrent and/or refractory solid tumors

D. Sullivan, R. Lush, J. Mahany, A. Dellaportas, A. Scuto, A. Daud, D. Colevas, K. Bhalla

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 136 KB

english, 2004

542

537 Multidrug-resistant tumors treated with Epothilone B in combination with clinically relevant doses of ionizing radiation

B. Hofstetter, V. Vuong, A. Broggini-Tenzer, M. Wartmann, D. Fabbro, S. Bodis, G. Folkers, M. Pruschy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 273 KB

english, 2004

543

538 New synthetic Epothilone derivative ZK-EPO inhibits tumors generally resistant to chemotherapy

U. Klar, J. Hoffmann, A. Rotgeri, B. Buchmann, W. Schwede, W. Skuballa, R.B. Lichtner

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

544

539 Comparative pharmacokinetic (PK) study of a cremophor-free, protein stabilized, nanoparticle formulation (ABI-007) and a cremophor-based formulation of paclitaxel (P) in patients with advanced solid tumors

M.J. Hawkins, J.R. Lane, L. Harris, P.J. Williams, V. Trieu, P. Soon-Shiong, N. Desai

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

545

540 Clofarabine administered weekly to adult patients with advanced solid tumors in a phase I dose-finding study

C.C. Cunningham, J. Nemunaitis, N. Senzer, S. Vukelja, D. Richards, V. Vukovic, S. Weitman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 270 KB

english, 2004

546

541 Effects of bisintercalating DNA threading agents on global gene expression

Z. Zihlif, D. Catchpoole, Z. He, L.P.G. Wakelin, B.W. Stewart

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

547

542 Synthesis, lipophilicity and cytotoxicity of new oxaliplatin derivatives

M.A. Jakupec, M. Galanski, L. Habala, A.A. Nazarov, C. Rappel, S. Slaby, A. Yasemi, N.G.v. Keyserlingk, B.K. Keppler

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

548

543 In vitro evidences on the role of the halogenoacrylic moiety in modulating brostallicin mechanism of action

I. Beria, S. Marchini, M. Colombo, M. Broggini, C. Geroni

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 279 KB

english, 2004

549

544 Atomic force microscopy study of structural transitions of supercoiled DNA in response to Poly(ADP-ribose)polymerase-1 protein binding

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

550

545 Biological effects of G-Quadruplex binding agents in various human cancer cell lines

M. Gunaratnam, O. Greciano, C. Martins, C.M. Schultes, S. Neidle, L.R. Kelland

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

551

546 A novel aureolic acid antibiotic analogue has potent anti-proliferative activity and induces multiple changes in gene expression in ovarian cancer cells

V. Albertini, S. Vignati, A. Rinaldi, F. Bertoni, J. Rohr, G. Carbone, C. Catapano

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

552

547 DNA adduct formation by C-1748, a potent antitumor 4-methyl-1-nitroacridine of lowered toxicity

J. Grzeskowiak, A. Bartoszek, B. Wysocka-Skrzela, J. Konopa, R. Tiwari

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 291 KB

english, 2004

553

548 Oral administration of clofarabine daily × 5 every 4 weeks in patients with advanced solid tumours in a phase I and pharmacokinetic study

C.C. Cunningham, J. Nemunaitis, N. Senzer, S. Anthony, P. Bonate, S. Weitman, L.A. Hammond

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

554

549 HKH40A, potent agent agaist GI cancers, targets p53 or when that is mutated, Akt

C.J. Michejda, T. Kosakowska-Cholody, H. Hariprakasha, Y. Pommier, S. Antony, B.I. Carr, S. Kar, M.G. Hollinghead, A.P. Monks

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

555

550 Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer

S.Q. Chu, G. Schwartz, M. Beeram, A. Patniak, M. Mita, J. Jimeno, L. Lopez-Larazo, M. Izquerido, L. Flores, E. Rowinsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 273 KB

english, 2004

556

551 Irofulven (IROF) enhances the antiproliferative effects of oxaliplatin (oxa) in human colon and breast cancer cells

M. Serova, F. Calvo, E. Cvitkovic, F. Koeppel, V. Poindessous, A.K. Larsen, E.S. Van Laar, S.J. Waters, E. Raymond

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

557

552 Genetic alterations and histology are related to the distinct responses of xenografted gliomas to different alkylating agents

P. Leuraud, L. Taillandier, J. Medioni, J.-Y. Delattre, M. Sanson, M.-F. Poupon

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

558

553 Activation of trans geometry in bifunctional mononuclear platinum complexes by combining aliphatic and aromatic amines. Mechanistic studies on antitumor action

C. Navarro-Ranninger, F.J. Ramos-Lima, O. Vrana, O. Novakova, A.G. Quiroga, V. Brabec

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 270 KB

english, 2004

559

554 A broad panel of screening assays for mutation and methylation assessment of genes involved in the pathological development and therapeutic treatment of NSCLCa broad panel of screening assays for mutation and methylation assessment of genes involved in the pathological development and therapeutic treatment of NSCLC: utility for therapeutic monitoring

S. Lilleberg, J. Durocher, C. Zhi, C. Sanders, B. Walters, M. Geimer, J. Hempel, D. Foster, P. Fogle, C. Wasserburger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

560

555 Metabolic activation of satraplatin by haemoglobin in vitro

M. McKeage, J. Carr, M. Tingle

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

561

556 Histone deacetylase inhibitors induce chromatin decondensation by down-regulation of proteins involved in the maintenance of heterochromatin

D.C. Marchion, E. Bicaku, A.I. Daud, D.M. Sullivan, P.N. Munster

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

562

557 Evidences for G-quadruplex formation in the mitochondrial genome

N. Dias, J.F. Goossens, L. Lacroix, J.L. Mergny, F. Rosu, P. Colson, M.P. Teulade-Fichou, A. Lansiaux, C. Bailly

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

563

558 Antitumor activity of brostallicin on human prostatic cancer cells: fundamental role of combination with hypomethylating agents

M.A. Sabatino, C. Geroni, M. Broggini

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

564

559 The novel DNA cross-linking agent SJG-136 (NSC 694501) exhibits potent, selective and p53-independent cytotoxicity in human chronic lymphocytic leukaemia cells

C. Pepper, R. Hambly, C. Fegan, P. Delavault, D. Thurston

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

565

560 Kahalalide F (KF) induces apoptosis-independent cell death that involves ErbB3 downregulation and inhibition of Akt signalling

M.L. Janmaat, F.A.E. Kruyt, J.M. Jimeno, J.A. Rodriguez, G. Giaccone

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 143 KB

english, 2004

566

561 The marine, anticancerous compound dehydrothyrsiferol affects integrin mediated adhesion of human breast cancer cells

M.K. Pec, J.J. Fernández, M.L. Souto, F. Díaz-González

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 276 KB

english, 2004

567

562 The combination of ET-743 and Irinotecan is active in preclinical models in rhabdomyosarcoma

D. Meco, A. Riccardi, P. Ubezio, M. D'Incalci, J.M. Jimeno, J.C. Tersero Lopez, R. Riccardi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

568

563 Distinct effects of proteasome inhibition by a novel inhibitor in lymphoid cells

C. Miller, M. Dujka, S. Ruiz, S. Neuteboom, M. Palladino, D. McConkey, J. Chandra

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

569

564 In vitro cytotoxic activity of NBT-272, a novel quassinoid analog

L. Helson, J. McChesney, P. Bartyzel

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

570

565 Antitumoral activity of a polyisoprenylated benzophenone (CLU-502) isolated from Clusia sp

D. Diaz-Carballo, D. Strumberg, S. Seeber, R.A. Hilger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

571

566 Novel mTOR inhibitors with improved pharmacological properties over rapamycin

M.A. Gregory, S. Gaisser, R.E. Lill, H. Hong, B. Wilkinson, H. Petkovic, R. Sheridan, J. Staunton, P.F. Leadlay, M. Zhang

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

572

567 Parthenolide sensitizes ultraviolet (UV) B-induced apoptosis via PKC but independent of AKT

Y.K. Won, C.N. Ong, H.M. Shen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

573

568 Real time imaging of cancer therapeutic effects of a natural product turmeric in cell culture and animal models

T. Chaudhuri, Z. Cao, K. Zinn

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 279 KB

english, 2004

574

569 A new antitumor compound, ECO-04601: preclinical evaluation and in vivo efficacy in glioma

V. Dimitriadou, B. Simard, S. Boccard, L. Pelletier, J. McAlpine, E. Zazopoulos, P. Falardeau, F. Berger, C. Farnet

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

575

570 In vitro and in vivo characterizations of naturally occurring BBls in reversal of p-gp mediated multidrug resistance

W. Fan, X. Zhu, J. Dziadyk, M. Sui

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 130 KB

english, 2004

576

571 Bioavailability and pharmacokinetic study of the novel oral C-seco taxane derivative IDN 5390 in mice

M. Zaffaroni, R. Frapolli, A. Riva, C. Manzotti, P. Morazzoni, E. Bombardelli, M. D'Incalci, M. Zucchetti

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 262 KB

english, 2004

577

572 An investigation of the anticancer mechanism of citrus flavonoids tangeretin and nobiletin

K. Morley, J. Koropatrick

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

578

573 A mechanism for cancer prevention by carotenoids: the role of Nrf2 transcription factor

J. Levy, A. Ben-Dor, L. Gheber, M. Danilenko, M. Steiner, N. Dubi, K. Linnewiel, Y. Sharoni

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

579

574 Comparative study of anticancer and apoptosis-inducing activity of stilbene derivatives in HL-60 human promyelocytic leukemia cells

Z. Horvath, N. Handler, P. Saiko, S. Madlener, C. Illmer, M. Murias, M. Fritzer-Szekeres, T. Erker, W. Jäger, T. Szekeres

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

580

575 Effect of silybin and docetaxel on LNCap prostate cell growth and total PSA levels

R. Bernacki, P. Pera, P. Morazzoni, C. Manzotti, A. Riva, E. Bombardelli

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

581

576 MVA-FCU1: a highly potent gene-based chemotherapy providing 5-FU local delivery

P. Erbs, A. Findeli, P. Cordier, J. Kintz, C. Hoffmann, K. Dott, V. Calenda, J.M. Balloul

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

582

577 Bio-reductive prodrug approach to target angiogenesis in tumours

E. Blanche, C.J. Moody, J.L. Whatmore, L. Maskell

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 135 KB

english, 2004

583

578 PSA-activated prodrugs for the treatment of prostate cancer

B.W. McLean, B. Kapdee, D. Stoll, J.A. Whiteway, A. Purac, C. Braun, T.J. Borgford

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 270 KB

english, 2004

584

579 Design and synthesis of difluoromethylphosphonamidates for prodrugs of non-hydrolyzable phosphotyrosine peptidomimetics

R. Borch, I. Boutselis, R. Huang

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

585

580 In vitro release of 17-demethoxy-17-allylaminogeldannamycin from its prodrugs

E. Tabibi, L. Zhao, B.R. Vishnuvajjala, S.H. Yalkowsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

586

581 Lycopene, alone or combined with vitamin E, reduces orthotopic growth and plasma PSA release of PC-346C prostate tumors

J. Limpens, F.H. Schröder, C.M.A. de Ridder, C.A. Bolder, M.F. Wildhagen, U.C. Obermüller-Jevic, B. Nowakowsky, K. Krämer, W.M. van Weerden

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

587

582 Chemoprevention of ovarian cancer in primate model

M. Brewer, J. Ranger-Moore, Z. Hao, J. Wang, J. Wharton, D. Gershenson, C. Zou

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 280 KB

english, 2004

588

583 Serum proteomic biomarkers of a natural product in a prospective randomized placebo-controlled clinical trial in patients at risk for lung cancer

S. Baek, D. Campos, E. Izbicka, J. Jiang

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

589

584 Phase II trial design for radiation (XRT) modifiers: efficient evaluation of safety, XRT modifier effect, post-XRT cytostatic effect and relevant molecular markers

R. Mick, W.G. McKenna, S.M. Hahn

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

590

585 Analytical and multi-center clinical performance evaluation of a diagnostic device designed to analyze the expression of 11q23/MLL abnormal fusion transcripts in acute leukemia

N. Maroc, V. Castéras, A. Morel, A. Lamy de La Chapelle, C. Harrison, M. Griffiths, G. Mitterbauer-Hohendanner, S. Shurtleff, A. Koki, F. Hermitte

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 289 KB

english, 2004

591

586 Response assessment classification: effect of multiple measurement criteria and parameters

J. Colville, L.H. Schwartz, L. Wang, M. Mazumdar, J. Kalaigian, H. Hricak, D. Ilson, G.K. Schwartz

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

592

587 Development of proximity based assay to detect and quantify erbB (or Her) receptor dimerization in formalin fixed-paraffin embedded tissue sections

R. Dua, Y. Shi, A. Mukherjee, N. Glavas, S. GangaKhedkar, H. Pannu, J. Wallweber, P. Chan-Hui, S. Singh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

593

588 Prevalence of erbB/Her dimerization in breast cancer

S. Pidaparthi, Y. Shi, J. Wallwebber, P.-Y. Chan-Hui, S. Singh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

594

589 Gene expression profiling defines new molecular classes and predicts response to adjuvant anthracycline-based treatment in breast cancer patients: development of a biochip to predict prognosis and improve clinical management of breast cancer

N. Borie, P. Viens, F. Bertucci, J. Jacquemier, T. Bachelot, I. Treilleux, S. Deraco, S. Debono, F. Hermitte, A. Koki

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 294 KB

english, 2004

595

590 Reduction of EGFR/Her-1 dimerization and phosphorylation in colorectal tumors and normal skin correlates with clinical response to Tarceva

P. Chan-Hui, Y. Shi, M. Tang, S. Singh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 153 KB

english, 2004

596

591 p53 mutation with transdominance activity is an independent prognostic factor for endometrial cancer

N. Sakuragi, E. Steiner, H. Koelble, T. Moriuchi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 153 KB

english, 2004

597

592 Maspin gene expression is a prognostic factor in non-small cell lung cancer

H. Katakura, K. Takenaka, M. Nakagawa, M. Sonobe, H. Oyanagi, M. Adachi, H. Wada, F. Tanaka

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 153 KB

english, 2004

598

593 New biological assay to evaluate the pharmacodynamic effects of rapamycin in cancer patients

J.-M. Peralba, M. Zhao, S. Baker, K. Pandya, M. Hidalgo

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

599

594 Dielectrophoresis (DEP) as sorting technology for microdiagnosis in breast cancer

A.M. Gonzalez-Angulo, C. Das, J.M. Reuben, S. Krishnamurthy, W. Spohn, V. Jody, G.N. Hortobagyi, M.C. Hung, P.R. Gascoyne, M. Cristofanilli

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

600

595 Correlation between effects of PTK787/ZK 222584 on the interstitial fluid pressure of rat mammary tumours and their vasculature measured by contrast-enhanced MRI

S. Ferretti, P.R. Allegrini, P.M.J. McSheehy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

601

596 IC50 determination for receptor-targeted compounds and downstream signaling

H. Salimi-Moosavi, X. Jin, Y. Badal, S. Pidaparthi, P.-Y. Chan-Hui, S. Singh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 287 KB

english, 2004

602

597 Differential Her family receptor dimerization and downstream signaling in cancer cell lines

H. Salimi-Moosavi, P.-Y. Chan-Hui, S. Pidaparthi, S. Singh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

603

598 The cancer therapy evaluation program, National Cancer Institute initiative to enhance combination investigational agent clinical trials

S. Ansher, D. Shoemaker, M. Christian

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

604

599 Phase I and pharmacokinetic (PK) study of OSI-7904L in combination with Cisplatin (CDDP) in patients with advanced solid tumors

A. Ricart, S. Syed, D. Drolet, C. Quaratino-Baker, J. Horan, M. Rothenberg, A. Tolcher, E. Rowinsky

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 144 KB

english, 2004

605

600 Endothelin-1 antagonist selectively modulates tumor blood flow and potentiates responses to both chemotherapy and radiotherapy

P. Martinive, P. Sonveaux, C. Dessy, O. Feron

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 277 KB

english, 2004

606

601 Increased transport of nanoparticle albumin-bound paclitaxel (ABI-007) by endothelial gp60-mediated caveolar transcytosis: a pathway inhibited by Taxol

N. Desai, V. Trieu, R. Yao, E. Labao, T. De, P. Soon-Shiong

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

607

602 SMA-pirarubicin micelles: highly efficient tumor targeting and therapeutic effects without apparent toxicity

H. Maeda, K. Greish

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

608

603 Effect of membrane transport proteins on the disposition of vincristine in brain-tumor bearing mice

P. Guo, F. Zhou, M.G. Belinsky, G.D. Kruh, J.M. Gallo

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 268 KB

english, 2004

609

604 Secretory phospholipase A2 as tumour specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids

S.S. Jensen, L.T. Jensen, J. Davidsen, J.H. Gill, S.D. Shnyder, M.C. Bibby, P.T.L. Høyrup, K. Jørgensen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

610

605 Encapsulation of vinorelbine in sphingomyelin/cholesterol liposomes enhances the tumor exposure and antitumor activity of vinorelbine in human mammary and non-small cell lung cancer solid tumor models

S.C. Semple, E.C. Leng, Z.-N. Yuan, M.L. Eisenhardt, R. Leone, H.L. Sweet, P. Dhaliwal, R. Namdari, C.C. Flowers, S.K. Klimuk

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

611

606 Phase I and pharmacological study of AP5346, an HPMA copolymer-linked DACH platinum therapeutic, in patients with solid progressive tumors

M. Campone, J. Rademaker-Lakhai, J. Bennouna, D. Berton-Rigaud, S.B. Howell, R. de Boer, C.M. Baud, L. van Warmerdam, J.H. Beijnen, J.H.M. Schellens

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 134 KB

english, 2004

612

607 Tumour specific delivery of cytostatics encapsulated in novel phospholipase A2 degradable liposomes

S.S. Jensen, L.T. Jensen, J. Davidsen, J.H. Gill, S.D. Shnyder, M.C. Bibby, P.T.L. Høyrup, K. Jørgensen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

613

608 A new multifunctional drug delivery system based on polymalic acid to inhibit angiogenesis and invasion of human gliomas in vitro and in vivo

J.Y. Ljubimova, E. Holler, M. Fujita, N.M. Khazenzon, B. Lee, K.L. Black

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

614

609 KCa channel-mediated regulation of metastatic brain tumor permeability and proliferation

N. Ningaraj, M. Rao, K. Kasisomayajula, A. Narasanna, R. Thompson, D. Hallahan, J. Gore, T. Yankeelov

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

615

610 Mutant bad effectively inhibited human nsclc xenografts in nude mice

Y. Zou, B. Zhou, R. Perez-Soler

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 287 KB

english, 2004

616

611 Introduction of specificity into cytotoxic drugs and improvement of therapeutic index by kinase-mediated trapping

M. Newman, S. Aspland, C. Ballatore, R. Castillo, J. Desharnais, T. Eustaquio, Z. Guo, Q. Li, C. Sun, A. Castellino

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

617

612 Mitochondrial-mediated apoptosis is induced by cationic polymers used in gene transfer

S.M. Moghimi, P. Symonds, A.C. Hunter, G. Debska, A. Szewczyk, J.C. Murray

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

618

613 Plasma and tissue distribution of selenium after 5-methylselenocysteine (MSC) or seleno-L-methionine (SLM) in mice bearing human tumor xenografts

R.G. Azrak, L. Pendyala, S. Cao, F. Durrani, J. Prey, M. Fakih, Y.M. Rustum

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 281 KB

english, 2004

619

614 Increased tumor extravasation with an elastin-like polypeptide systemic thermal pump

M. Dreher, W. Liu, C. Michelich, M. Dewhirst, A. Chilkoti

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

620

615 Preliminary results of a phase I/II study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer

G.A. Otterson, M.A. Villalona-Calero, A. Grainger, W. Hicks, J. Murren, J. Ellerton, C. Mojzisik, M. Gerber, D. Westaway

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

621

616 Elimination of liposomes by apheresis-techniques

G. Puetz, J. Eckes, H. Wieland

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

622

617 Pharmacodynamic analysis of surrogate tissue responses to the demethylating agent 2′-deoxy-5-azacytidine (Decitabine)

K. Appleton, G. Strathdee, J. Plumb, A. Schaetzlein, S. Reade, S. Barrett, C. Lee, I. Judson, P. Vasey, R. Brown

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

623

618 Breast cancer resistance protein (BCRP) expression, function and promoter methylation in multiple myeloma: potential mechanism of drug resistance

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

624

619 Analogies in imatinib-resistant threonine-to-isoleucine mutation in BCR-ABL, KIT and PDGFRa: a combined experimental/computational approach

S. Pricl, M. Ferrone, M.S. Paneni, E. Tamborini, T. Negri, E. Gabanti, M.S. Lagonigro, S. Pilotti, A. Greco, M.A. Pierotti

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 140 KB

english, 2004

625

620 Elevated expression of IL-8 and IL-8 receptors in prostate cancer cells correlates with disease progression and resistance to oxaliplatin

C. Murphy, J. Pettrigrew, A. Santinelli, P. Johnston, R. Montironi, D. Waugh

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

626

621 Disruption of the serine kinase SKY1 gene in yeast results in hypersensitivity to 5-fluorouracil (5-FU) and low expression of the human SKY1 ortholog SRPK1, in colorectal cancers correlates with prolonged overall survival after 5-FU treatment

E. Wiemer, P. Schenk, M. Brok, A. Boersma, M. van Rijnsoever, N. Zeps, B. Iacopetta, K. Nooter

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

627

622 Resistance to cytotoxic drugs is associated with changes in telomere length

V. Smith, F. Dai, G.J. Peters, H.H. Fiebig, A.M. Burger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 150 KB

english, 2004

628

623 Gene expression enhancement by inhibitors of methylation: potential role in augmentation of apoptosis induced by interferons (IFNs) in melanoma and renal cell carcinoma (RCC)

E.C. Borden, F.J. Rue, M.W. Fox, N. Beaulieu, D.W. Leaman, A.R. MacLeod

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 292 KB

english, 2004

629

624 Global identification of genes involved in 5-flurouracil resistance

W. Wang, E. Collie-Duguid, J. Cassidy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

630

626 Targeting McI-1 exhibits a strong single agent activity in hepatocellular carcinoma

W. Sieghart, D. Losert, S. Strommer, D. Cejka, M. Peck-Radosavljevic, V. Wacheck

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

631

625 Comparison of gene expression profiles in breast cancer cells treated with 5-fluorouracil, cisplatin or etoposide using cDNA microarray

M. Ahn, H. Lee, H. Oh, Y. Lee, I. Kim, J. Choi, G. Lee, D. Shin, M. Ahn

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 145 KB

english, 2004

632

627 The role of hypoxia-induced lysyl oxidase in cancer progression, tumor response to therapy and patient prognosis

J.T. Erler, A.J. Giaccia

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

633

628 Targeting Bcr/Abl and Src family kinases reverses Imatinib mesylate resistance in CML

J.Y. Wu, M. Talpaz, J. Stapley, S. Lee, N. Donato

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

634

629 Acquired irofulven-resistance is mediated by a novel and drug-specific resistance mechanism associated with overexpression of ABCA12

F. Koeppel, J.-P. Annereau, A. Escargueil, V. Poindessous, G. Szakacs, E. Raymond, E.S. Van Laar, S.J. Waters, M. Gottesman, A.K. Larsen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

635

630 Molecular mechanisms of resistance against the ruthenium compound KP1019

P. Heffeter, M.A. Jakupec, M. Pongratz, P. Chiba, M. Micksche, W. Körner, M. Hauses, B. Marian, B.K. Keppler, W. Berger

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 293 KB

english, 2004

636

631 Tumor associated fibroblasts have a profound impact on drug sensitivity of gastric cancer cells

K. Mayer, L. Gaedtke, I. Funke, K. Jauch, B. Mayer

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

637

632 Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance

Y.K. Shin, B.C. Yoo, E.K. Jeon, S.H. Hong, M.S. Jung, J.G. Park

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

638

633 Genetic variation in P-glycoprotein gene (ABCB1) and tipifarnib exposure

V. Ozdemir, Q. Li, R. Favis, S. Francke, B. Fijal, J.J. Perez Ruixo, P. Zannikos, P. Palmer, A. Thibault, N. Cohen

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

639

634 E2F-1 induction and MEK inactivation coordinates with p53-generated signals to switch chemotherapy-induced growth arrest to apoptosis in human colorectal HCT116 cancer cells

Z. Zhao, L. Zhuang, Y. Li, Q. Yu

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 291 KB

english, 2004

640

635 Inflammatory response might influence the pharmacokinetics (PK) and pharmacodynamics (PD) of Imatinib and CGP 74588 in patients with advanced gastro-intestinal-sarcoma (GIST)

C. Delbaldo, E. Chatelut, M. Ré, A. Deroussent, A. Mackrodt, A. Jambu, P. Berthaud, A. Le Cesne, G. Vassal

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

641

636 Promoter hypermethylation of the DNA repair gene mgmt is more frequent in secondary glioblastomas and is independent from other prognostic factors

M. Eoli, L. Bissola, F. Menghi, B. Pollo, A. Silvani, G. Broggi, A. Boiardi, G. Finocchiaro

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

642

637 Effective combinations of carboplatin with low doses of TRAIL, HGS-ETR1 and HGS-ETR2 in the TRAIL-sensitive HX62 human ovarian tumour cell line

B. Krishnan, M.G. Ormerod, S.B. Kaye, A.L. Jackman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

643

638 Acquired resistance to EGF receptor-targeted cancer therapy

Y. Lu, R. Luwor, K. Liang, X. Li, G. Mills, J. Mendelsohn, Z. Fan

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 284 KB

english, 2004

644

639 Characterization of the binding sites of P-glycoprotein by a functional flow cytometric assay

K. Breitbach, M. Wiese

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

645

640 Stat1 as mediator of acquired tumor radioresistance and potential target for anti-tumor therapy

N.N. Khodarev, E. Labay, M. Beckett, T. Darga, A. Halpern, B. Roizman, R.R. Weichselbaum

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

646

641 Inhibition of PDGF signaling attenuates radiation-induced pulmonary fibrosis

A. Abdollahi, M. Li, G. Ping, C. Plathow, H.-J. Groene, L.B. Lee, K. Lipson, P.H. Huber

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 141 KB

english, 2004

647

642 Molecular targeting of epidermal growth factor receptor (EGFR) positive gliomas for neutron capture therapy using boronated bioconjugates

R.F. Barth, G. Wu, W. Yang, P.J. Binns, K.J. Riley, H. Patel, J.A. Coderre, W. Tjarks, M.J. Ciesielski, R.A. Fenstermaker

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 290 KB

english, 2004

648

643 Radiosensitization of human prostate cancer by natural polyphenol inhibitor of Bcl-2/XL, (−)-gossypol, results in tumor regression

L. Xu, D. Yang, S. Wang, W. Tang, M. Liu, J. Chen, T. Lawrence, M.E. Lippman

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 153 KB

english, 2004

649

644 Selective inhibition of Ras, PI3-kinase and Akt isoforms can radiosensitize human carcinoma cell lines

E.J. Bernhard, I. Kim, K.A. Cengel, S.S. Bae, A. Fernandes, J. Wu, R.J. Muschel, W.G. McKenna, M.J. Birnbaum

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 153 KB

english, 2004

650

645 Radiotion sensitization of lung cancer through inhibition of MDM2

B. Lu, C. Cao, K. Niermann, D. Hallahan

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 287 KB

english, 2004

651

646 Enhancement of radioresponse by phosphatidylinositol 3-kinase inhibitor in radioresistant murine hepatocarcinoma

J. Seong, W. Kim, J. Kim

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

652

647 Modulation of tumor hypoxia in response to treatment with ionizing radiation and the VEGFR inhibitor PTK787/ZK222584

O. Riesterer, M. Honer, C. Oehler, V. Djonov, S. Ametamey, S. Bodis, M. Pruschy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

653

648 In vivo efficacy of photodynamic therapy in xenografts of retinoblatoma

P. Leuraud, L. Taillandier, J. Medioni, J.-Y. Delattre, M. Sanson, M.-F. Poupon

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 137 KB

english, 2004

654

649 Update on the toxicity and response of a phase I trial of concurrent, daily gefitinib and radiation or chemo-radiation for patients with locally advanced squamous cell cancer of the head and neck (LASCCHN)

D. Raben, M. Kane, C. Chen, J. Song, L. Brualdi, A. Raben, K. Hu, S. Gollamudi, H. Quon, J. Dancey

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

655

650 Pathological complete response rate in esophageal cancer after endoscopically delivered intratumoral (IT) injections of TNFerade combined with neoadjuvant chemoradiotherapy (CRT): a phase I/II trial

N. Senzer, S. Swisher, T. Reid, A. Mauer, M. Posner, H. Pinto, K. Chang, A. Forastiere, R. Soetikno, J. Nemunaitis

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

656

651 Effects of celecoxib and irradiation treatment on prostate cancer cell lines

R. Handrick, C. Belka, B. Goecke, H. Faltin, P. Daniel, W. Budach, V. Jendrossek

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

657

652 Radiosensitization of tumor by caffeine encapsulated in liposomes

H.J. Park, J.S. Kim, E.J. Kim, C. Kim, S.W. Ha, C.W. Song, E.K. Choi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

658

653 Optimization of novel antiangiogenic treatment modalities in combination with ionizing radiation

O. Riesterer, C. Oehler, D. Zingg, V. Vuong, A. Broggini-Tenzer, D. Fabbro, S. Bodis, M. Pruschy

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

659

654 Gene expression profiling of human glioblastoma. A translational research study to the randomized trial EORTC 26981/NCIC CE.3 testing radiotherapy ± temozolomide

A. Murat, E. Migliavacca, T. Shay, M. Weller, J. Kros, C. Marosi, R. Janzer, E. Domany, M. Delorenzi, M. Hegi

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 138 KB

english, 2004

660

655 Pre-clinical studies of concomitant taxanes and ionizing radiation therapy: local and systemic anti-tumor effects

L. Liebes, B. Ng, S. Demaria, M. Devitt, J. Babb, S. Formenti

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

661

656 Influence of Irinothecan and SN-38 on the irradiation response of WHO3 human esophageal tumour cells under hypoxic conditions

L. Bohm, C. van Rensburg

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

662

657 Effects of Fulvestrant on oestrogen receptor levels during long-term treatment of patients with advanced breast cancer

E. Gutteridge, J. Robertson, K. Cheung, S. Pinder, A. Wakeling

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 146 KB

english, 2004

663

658 An essential role for AIB1 phosphorylation in tamoxifen resistance

J. Shou, R. Cook, G. Chamness, K. Osborne, R. Schiff

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 282 KB

english, 2004

664

659 ER-beta expression in rhabdomyosarcoma cells is essential for activation of caspase mediated apoptosis after treatment with tamoxifen

S. Somme, D. Malkin

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

665

660 Fulvestrant does not markedly inhibit human cytochrome p450 isozymes: results from in vitro studies

M. Harrison, D. McKillop, C. Dilworth

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 139 KB

english, 2004

666

661 An androgen-receptor (AR)-negative human prostate cancer xenograft induces mouse-derived osteogenesis

P. Mathew, C. Sikes, A. Multani, C. Bucana, V.G. Prieto, P. Troncoso, K. Raymond, C. Logothetis, N. Navone

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 163 KB

english, 2004

667

Presenting authors list

Journal:

European Journal of Cancer Supplements

Year:

2004

File:

PDF, 239 KB

2004

668

Author index

Journal:

European Journal of Cancer Supplements

Year:

2004

File:

PDF, 1.32 MB

2004

669

Subject index

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 241 KB

english, 2004

670

51 HSV-tk gene transduction enhances proliferation rate and COX-2 expression in rat gliosarcoma cells

Al-Athamen, K., Konson, A., Rimon, G., Danon, A., Agbaria, R.

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

671

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

Tolcher, A., O'Leary, J.J., DeBono, J., Molpus, K., Woodard, C., Warnat, M., Liau, K., Noe, D., Healey, D., Huberman, M.

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

672

472 Assessment of the therapeutic activity and dose optimization for the anthracycline RTA 744 (WP744) using a xenograph model

Thapar, N., Meyer, C., Huff, W., Culotta, K., Fokt, I., Priebe, W., Madden, T., Johansen, M.

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 147 KB

english, 2004

673

136 Regulation of tumour angiogenesis and cell survival by integrin-linked kinase (ILK): pre-clinical evaluation of novel small molecule inhibitors

Dedhar, S., Troussard, A., Tan, C.

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 148 KB

english, 2004

To build up a library is to create a life. It’s never just a random collection of books.

— Carlos María Domínguez

Official channel

Z-Library Desktop Launcher

Tor version

Z-Library

Z-Library Since 2009 support@z-lib.do

EnglishРусскийEspañolItalianoελληνικάاللغة العربيةBahasa IndonesiaBahasa Malaysiaहिन्दीDeutschFrançaisPortuguêsУкраїнськаPolski中文繁體中文日本語Tiếng ViệtAzərbaycan DiliՀայոց լեզուภาษาไทยTürk Diliქართველიবাংলাپښتوతెలుగుاردو한국어SrpskiБългарски